IT-101 Agreement



 Exhibit 10.2 
 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN
APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 IT-101 AGREEMENT 
 THIS IT-101 AGREEMENT (“Agreement”), dated as of June 23, 2009 (the “Effective Date”), is by and between CALANDO
PHARMACEUTICALS, INC., a Delaware corporation having its principal place of business at 129 North Hill Avenue, Pasadena, California 91106 (hereinafter referred to as “Calando”), and CERULEAN PHARMA INC., a Delaware corporation,
having its principal place of business at 161 First Street, Cambridge, Massachusetts 02142 (hereinafter referred to as “Cerulean”). 
 INTRODUCTION 
 WHEREAS, Calando has developed IT-101 (as defined below); and 
 WHEREAS, Cerulean is engaged in the research, development and commercialization of nanopharmaceuticals and desires to develop and commercialize IT-101
upon the terms and conditions set forth herein; 
 NOW, THEREFORE, in consideration of the mutual covenants and promises contained herein and
other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Calando and Cerulean agree as follows: 
 SECTION 1. DEFINITIONS 
 As used in this Agreement, the following terms, whether used in the singular or plural, shall have
the following meanings: 
 1.1 “Affiliate” means any entity which directly or indirectly controls, is controlled by or is
under common control with another entity. For purposes of this Section 1.1, “control” means (a) in the case of corporate entities, direct or indirect ownership of at least fifty percent (50%) of the stock or shares entitled
to vote for the election of directors and (b) in the case of non-corporate entities, direct or indirect ownership of at least fifty percent (50%) of the equity interest with the power to direct the management and policies of such
non-corporate entities. The Parties acknowledge that, in the case of certain entities organized under the laws of certain countries, the maximum percentage ownership permitted by law for a foreign investor may be less than fifty percent (50%), and
in such case such lower percentage shall be substituted in the preceding sentence; provided, that such foreign investor has the power to direct the management and policies of such entity. 
 1.2 “Annual Net Sales” means the worldwide aggregate Net Sales of the Licensed Product during a calendar year. 
 1.3 “Arrowhead” means Arrowhead Research Corporation, a Delaware corporation. 
 1.4 “Assigned IP” means (a) the Assigned Patent Rights; (b) the Patent Files (as defined in the Platform Agreement);
(c) all inventions disclosed in the Assigned Patent Rights (other than those disclosed as prior art of a Third Party); and (d) the right to recover for past infringement of the Assigned Patent Rights. 







 1.5 “Assigned Patent Rights” means the Patent Rights set forth in Exhibit A and
all Counterparts thereof. 
 1.6 “Calando Indemnitees” means Calando, its Affiliates, and the agents, directors, officers
and employees of Calando and its Affiliates. 
 1.7 “Calando Liabilities” means any and all liabilities or obligations
(whether known or unknown, absolute or contingent, liquidated or unliquidated, due or to become due and accrued or unaccrued, and whether claims with respect thereto are asserted before or after the Effective Date) of Calando. 
 1.8 “Caltech” means California Institute of Technology. 
 1.9 “Caltech Agreement” means that License Agreement between Caltech and Calando (formerly known as Insert Therapeutics, Inc.), dated May 22, 2000, as amended on December 10,
2001, January 13, 2003 and June 19, 2009. 
 1.10 “Caltech Joint Patent Rights” means the subset of the
Licensed Patent Rights set forth in Exhibit B and all Counterparts thereof. 
 1.11 “Caltech Sole Patent Rights”
means the subset of the Licensed Patent Rights set forth in Exhibit C and all Counterparts thereof. 
 1.12 “Cerulean
Indemnitees” means Cerulean, its Affiliates, and the agents, directors, officers and employees of Cerulean and its Affiliates. 
 1.13 “Change of Control” means (a) the closing of a merger, tender offer, share exchange, reorganization, consolidation or other similar transaction involving Cerulean in which the persons who beneficially own
Cerulean’s voting securities immediately prior to such transaction would, immediately after such transaction, beneficially own less than fifty percent (50%) of the voting securities of the surviving entity; or (b) a sale or other
transfer to a Third Party of all or substantially all of Cerulean’s assets or business relating to this Agreement. For purposes hereof, “beneficial ownership” shall have the meaning provided in Rule 13d-3 under the Securities Exchange
Act of 1934. 
 1.14 “Clinical Trial” means any clinical trial of the Licensed Product or any other administration of the
Licensed Product prior to receipt of a Regulatory Approval. 
 1.15 “Collective Patent Rights” means the Assigned Patent
Rights and the Licensed Patent Rights. 
 1.16 “Combination Therapy” means the Licensed Product and a separate
pharmaceutical product sold by Cerulean or its Affiliates in combination for co-administration. 
 1.17 “Commercially Reasonable
Efforts” means, with respect to the Licensed Product, taking such actions, exerting such effort and employing such resources as would normally be taken, exerted or employed by a comparably-sized company in the biotechnology industry for a
product of similar market potential at a similar stage of its product life as the Licensed Product, taking into account the phase of development of, and technical risks relating to, the product, the development and proprietary positions of third
parties, the regulatory structure involved, the 

  

 2 








 
likely cost of goods, the competitiveness and size of the relevant marketplace, and the potential profitability of the product, when utilizing sound and
reasonable scientific, business and medical practice and judgment. 
 1.18 “Confidential Information” means, with respect to
a Party (the “Disclosing Party”) all proprietary information, patentable or otherwise, of the Disclosing Party (whether owned by the Disclosing Party or disclosed by a Third Party to the Disclosing Party under an obligation of
confidentiality) which is disclosed by or on behalf of such Party to the other Party (the “Receiving Party”) pursuant to and in contemplation of this Agreement, including information pertaining to chemical substances, therapeutic
agents, pharmaceutical compositions, drug delivery systems, formulations, processes, techniques, methodologies, data, reports, know-how, expertise, sources of supply, patent positioning and business plans. Confidential Information of the Disclosing
Party includes “Proprietary” Information of the “Discloser”, each as defined in the Prior Confidentiality Agreement. The elements of Assigned IP described in Sections 1.4(a), (b) and (c) shall be treated as Confidential
Information of Cerulean, except to the extent that they have been or are later disclosed by the publication of any patent or patent application. Any sublicense agreements disclosed by a Party to the other Party pursuant to Section 3.2 shall be
treated as Confidential Information of the Party entering into such sublicense agreement. 
 1.19 “Control” or
“Controlled” means, with respect to an entity and an item of Know-How or any intellectual property right, the possession of the right (whether by ownership, license or otherwise (other than pursuant to a license granted under this
Agreement)) by such entity or its Affiliates, to assign, or grant a license, sublicense or other right to or under, such Know-How or intellectual property right as provided for herein without violating the terms of any agreement or other arrangement
with any Third Party. 
 1.20 “Counterparts” means: 
 (a) with respect to a patent, the following items, collectively: any patent applications from which such patent issued, and all patents and patent
applications described in clause (b) with respect to each such patent application; 
 (b) with respect to a patent application
(including any provisional application), the following items, collectively: (i) all divisionals, continuations and continuations-in-part of such patent application; (ii) any patents (including certificates of correction) issuing from such
patent application or any patent application described in clause (i); (iii) all patents and patent applications based on, corresponding to or claiming the priority date(s) of any of the patents and patent applications described in clauses
(i) or (ii); (iv) any substitutions, extensions (including supplemental protection certificates), registrations, confirmations, reissues, re-examinations and renewals of any of the patents described in clauses (ii) or (iii); and
(iv) foreign counterparts of any of the foregoing. 
 1.21 “Covered” means, with respect to the Licensed Product and a
particular patent, that, but for a license granted to a Party under a Valid Claim included in such patent, or, with respect to an Assigned Patent Right, but for the assignment of such patent, the manufacture, use, offer for sale, sale or importation
of the Licensed Product would infringe such Valid Claim. 
 1.22 “Cyclodextrin System” means any cyclodextrin-based polymer
drug delivery system developed by Calando prior to the Effective Date and any improvements thereto developed during the Term. 
  

 3 








 1.23 “FDA” means the United States Food and Drug Administration or any successor agency
thereto. 
 1.24 “Field” means the treatment and/or prevention of disease in humans. 
 1.25 “First Commercial Sale” means, with respect to the Licensed Product in a country, the first bona fide sale of the Licensed Product
following the first receipt of a Regulatory Approval for the Licensed Product to permit use or consumption of the Licensed Product by the general public in such country. Transfers of Licensed Product for Clinical Trial purposes shall not be
considered a First Commercial Sale. 
 1.26 “HIPAA” means the Health Information Portability and Accountability Act, as
amended. 
 1.27 “IND” means a United States investigational new drug application or its equivalent or any corresponding
application of another country. 
 1.28 “IT-101” means the product described on Exhibit E. 
 1.29 “IT-101 IND” means IND [***]. 
 1.30 “Know-How” means any ideas, concepts, discoveries, developments, information and inventions, whether or not patentable, including materials, products, laboratory, pre-clinical and clinical data,
expertise, know-how, processes, techniques, any other scientific or technical information and Regulatory Documentation. 
 1.31
“Knowledge” means (a) with respect to Calando, the actual knowledge of the following individuals (together with any knowledge that a person in such person’s position would be expected to obtain given the exercise of
reasonably prudent scientific and business diligence in accordance with the standards of companies in the biotechnology industry): [***] (collectively, the “Calando Representatives”); and (b) with respect to Cerulean,
the actual knowledge of the following individuals (together with any knowledge that a person in such person’s position would be expected to obtain given the exercise of reasonably prudent scientific and business diligence in accordance with the
standards of companies in the biotechnology industry): [***]. 
 1.32 “Licensed IP” means, collectively, the Licensed
Know-How and Licensed Patent Rights. 
 1.33 “Licensed Know-How” means all Know-How Controlled by Calando as of the
Effective Date or during the Term which both (a) relates to the Cyclodextrin System and/or Calando’s research and development of Other Licensed Products or IT-101 and (b) is necessary or reasonably useful to (i) conduct research
and development on the Cyclodextrin System, including making improvements thereto, or (ii) research, develop, make, have made, use, market, offer to sell, distribute, sell and/or import the Other Licensed Products or IT-101. Without limiting
the generality of the foregoing, Licensed Know-How shall include all Know-How developed, applied or acquired by Calando prior to the Effective Date that (A) pertains to the use of the Cyclodextrin System, (B) is a process for manufacturing
the cyclodextrin polymer, or precursors thereto, employed in the Cyclodextrin System, (C) is a process for conjugating or complexing therapeutic agents to the cyclodextrin polymer employed in the Cyclodextrin System, or (D) is data
generated by Calando in its research and development of the Other Licensed Products or IT-101. 
  

 4 








 1.34 “Licensed Patent Rights” means all Patent Rights Controlled by Calando as of the
Effective Date or during the Term which both (a) relate to the Cyclodextrin System and/or Calando’s research and development of Other Licensed Products or IT-101 and (b) are necessary or reasonably useful to (i) conduct research
and development on the Cyclodextrin System, including making improvements thereto, or (ii) research, develop, make, have made, use, market, offer to sell, distribute, sell and/or import the Other Licensed Products or IT-101. Without limiting
the generality of the foregoing, Licensed Patent Rights shall include the Caltech Joint Patent Rights, the Caltech Sole Patent Rights and the RNAi Patent Rights. For the sake of clarity, the Licensed Patent Rights exclude the Assigned Patent Rights.

 1.35 “Licensed Product” means IT-101 formulated for intravenous, intraarterial, intrathecal and/or intraperitoneal
therapy. 
 1.36 “NDA” means a United States new drug application or its equivalent or any corresponding application of
another country. 
 1.37 “Net Sales” means, with respect to the Licensed Product, the gross amount invoiced by Cerulean or
its Affiliates on sales or other dispositions of the Licensed Product to a Third Party less the sum of (a) commercially reasonable trade, cash and quantity discounts, (b) credit or allowances given or made for recall, rejection or return
of previously sold Licensed Products, (c) commercially reasonable rebates, chargebacks or retroactive price reductions, (d) out of pocket charges for insurance, postage, handling, freight and other transportation costs which are invoiced
by Cerulean or its Affiliates, (e) government-mandated rebates and (f) customs, duties, surcharges, sales, transfer and other excise taxes levied on the sale, transportation, delivery or use of such Licensed Product, including any tax such
as a value added or similar tax or government charge, borne by the seller thereof, other than franchise or income tax of any kind whatsoever. 
 Net Sales shall not include any transfers of the Licensed Product for clinical trial purposes or any transfers of reasonable quantities of the Licensed Product as samples or as donations. 
 Net Sales shall not include any transfer between Cerulean and any of its Affiliates for resale. If Cerulean or an Affiliate sells the Licensed Product to
a distributor or other Third Party, Net Sales shall be based on the gross amount invoiced by Cerulean or the Affiliate from the sale of Licensed Product to such distributor or Third Party. 
 If Cerulean or any of its Affiliates makes a sale of the Licensed Product for other than monetary value, such Licensed Product shall be deemed sold
hereunder. The gross revenues to be included in Net Sales for any such deemed sales shall be the average price of “arms length” sales by Cerulean and its Affiliates during the calendar quarter in which such deemed sale occurs or, if no
such “arms length” sales occurred during such period, during the last calendar quarter in which such “arms length” sales occurred. 
 If the Licensed Product is sold in combination with another pharmaceutical product as part of a Combination Therapy in a country, then, for the purpose of calculating royalties owed under this Agreement on sales of
such Licensed Product, Net Sales shall be the lesser of: 
 (i) Net Sales of such Licensed Product in such country, or 
  

 5 








 (ii) the product of: 
 (A) Net Sales of such Combination Therapy (calculated applying the definition of Net Sales hereunder to such Combination Therapy in the same manner as applied to Licensed Product) in such country, and 
 (B) the fraction A/(A+B), where A is the average invoice price of such Licensed Product in such country, and B is the average invoice prices of the
other pharmaceutical product(s) in such Combination Therapy in such country; provided, however, that, if in a specific country the other pharmaceutical product(s) in such Combination Therapy are not sold separately in such country but
the Licensed Product is sold separately in such country, the fraction shall be A/C, where A is the average invoice price of the Licensed Product in such country and C is the invoice price of the Combination Therapy; provided, further,
however, that, if in a specific country the Licensed Product is not sold separately in such country but the other pharmaceutical products are sold separately in such country, the fraction shall be C-B/C, where B is the average invoice price
of the other pharmaceutical product(s) in the Combination Therapy in such country and C is the invoice price of the Combination Therapy in such country; and provided, further, however, that, if in a specific country neither the
Licensed Product nor any of the other pharmaceutical products are sold separately in such country, then the fraction shall be negotiated in good faith by the Parties. 
 1.38 “Other Licensed Product” means any product licensed to Cerulean pursuant to the Platform Agreement. 
 1.39 “Party” means Calando or Cerulean; “Parties” means Calando and Cerulean. 
 1.40 “Patent Right” means any patent application (including any provisional application) or patent, and any Counterpart thereof. 
 1.41 “Phase 1 Clinical Trial” means a human clinical trial that is intended to initially evaluate the safety, tolerance or pharmacological or antigenic effects of the Licensed Product in human
subjects, or that is otherwise described in 21 CFR 312.21(a) or its foreign counterpart. 
 1.42 “Phase 2 Clinical Trial”
means a human clinical trial that is intended to initially evaluate the dosing and effectiveness of the Licensed Product, or that is otherwise described in 21 CFR 312.21(b) or its foreign counterpart. 
 1.43 “Phase 3 Clinical Trial” means a human clinical trial that is prospectively designed to demonstrate statistically whether the
Licensed Product is safe and effective to prevent or treat a particular indication in a manner sufficient to obtain Regulatory Approval to market the Licensed Product, or that is otherwise described in 21 CFR 312.21(c) or its foreign counterpart.

 1.44 “Platform Agreement” means the Platform Agreement entered into by the Parties on the Effective Date. 
 1.45 “Prior Confidentiality Agreement” means the Mutual Confidentiality Agreement between the Parties dated February 4, 2009.

 1.46 “Regulatory Approval” means, with respect to the Licensed Product in a country or regulatory jurisdiction, any and
all approvals (including any applicable governmental price and reimbursement approvals), licenses, registrations, or authorizations of the relevant Regulatory Authority necessary for the manufacture, use, storage, import, transport, promotion,
marketing and sale of the Licensed Product in such country, including approvals of NDAs. 
  

 6 








 1.47 “Regulatory Authority” means any applicable government regulatory authority
involved in granting approvals for the marketing and/or pricing of a pharmaceutical product in a country or regulatory jurisdiction, including the FDA and foreign equivalents thereof. 
 1.48 “Regulatory Documentation” means, with respect to IT-101, the IT-101 IND, all information and documentation supporting the IT-101
IND, and all information or documentation filed, or otherwise communicated to the FDA, in support of, or otherwise in connection with, the IT-101 IND, including all laboratory, preclinical, clinical and manufacturing data, information and reports;
drug dossiers; master files; reports; records; investigator brochures; protocols; informed consents; sponsor and investigator forms; amendments; correspondence and other documentation. 
 1.49 “Relevant Agreement” means each agreement, other than a confidentiality agreement, between Calando and an Affiliate of Calando or a
Third Party currently in effect, whether or not relating to the Licensed Product, including any agreement regarding evaluation, research, development, collaboration, material transfer, manufacture, license, joint venture, non-competition, clinical
trial, lease of real property or equipment, line of credit, bank loan or other loan. 
 1.50 “Required Third Party Payments”
means payments (including upfront payments, annual maintenance fees, milestones and earned royalties) made by Cerulean or any of its Affiliates to a Third Party to license Know-How or Patent Rights in order to research, develop, make, have made,
use, market, offer to sell, distribute, sell and import the Licensed Product in the Field. 
 1.51 “Requisite Debt Holder Consent and
Release” means that each holder of a promissory note of which Calando is the maker (each a “Note” and, collectively, the “Notes”) has irrevocably, in writing, (a) consented to the transactions
contemplated by this Agreement and (b) released Cerulean and its Affiliates from, and agreed not to assert against Cerulean or its Affiliates or any of their respective assets (including the Licensed IP, Assigned IP and the Inventory), any
Liens, claims, rights or other interests it has or may have (i) in connection with or as a result of the transactions contemplated hereby, (ii) in, against or relating to any of the Licensed IP, Assigned IP and the Inventory and/or
(iii) relating to the Notes or any stock into which the Notes can be converted. 
 1.52 “Requisite Stockholder
Approval” means the approval of the license of the Licensed Patent Rights and Licensed Know-How and sale of the Assigned IP and the Inventory by Calando to Cerulean as contemplated by this Agreement by (a) a majority of the votes
represented by the outstanding shares of capital stock of Calando entitled to vote thereon and (b) a majority of the votes represented by the outstanding shares of capital stock of Calando entitled to vote thereon, other than shares of such
capital stock held by Arrowhead. 
 1.53 “RNAi Patent Rights” means the subset of the Licensed Patent Rights set forth in
Exhibit D and all Counterparts thereof. 
 1.54 “Sublicense Income” means all amounts received by Cerulean or any of
its Affiliates to the extent attributable to a license or sublicense granted to a Third Party of any of the Assigned Patent Rights, Licensed Patent Rights or Licensed Know-How (such Third Party, a 
  

 7 








 “Sublicensee”), including upfront payments, annual maintenance fees, milestone payments (including for
development, performance and sales milestones) and earned royalties, but: 
 (a) amounts received by Cerulean or its Affiliates as payments
for performing research, development (other than development milestone payments referenced in the foregoing paragraph of this Section 1.54), manufacturing or commercialization activities undertaken by Cerulean or any of its Affiliates for, or
in collaboration with, such Sublicensee will be excluded; provided, that such deduction to Sublicense Income is an amount no greater than the fully-burdened cost for Cerulean or its Affiliates in performing such activities and all
out-of-pocket costs paid by Cerulean or its Affiliates to Third Parties in connection with such activities; 
 (b) amounts received by
Cerulean or its Affiliates from such Sublicensee as the purchase price for Cerulean’s or any of its Affiliates’ debt or equity securities will be excluded; provided, that, with respect to any such securities which are
publicly traded on any securities exchange or NASDAQ, such deduction to Sublicense Income is an amount no greater than the fair market value of such debt or equity securities; 
 (c) if such Sublicensee will also pay an earned royalty on its sale of a Licensed Product, then amounts paid by such Sublicensee to Cerulean or its
Affiliates as a transfer price to purchase the relevant Licensed Product or any component thereof will be excluded; and 
 (d) if such
Sublicensee will not also pay an earned royalty on its sale of a Licensed Product, then amounts paid by such Sublicensee to Cerulean or its Affiliates as a transfer price to purchase the relevant Licensed Product or any component thereof will be
excluded, but only up to the actual cost of goods of such Licensed Product or component; provided, however, that, for the sake of clarity, any portion of such transfer price greater than the actual cost of goods shall not be so
excluded. 
 1.55 “Third Party” means any person other than the Parties and their Affiliates. 
 1.56 “Valid Claim” means a claim of an unexpired issued patent which has not been withdrawn, cancelled or disclaimed nor held invalid or
unenforceable by a court of competent jurisdiction in an unappealed or unappealable decision. 
 1.57 Other Defined Terms. The word
“person” means any entity or individual. Each of the following definitions is set forth in the section of this Agreement indicated below: 
  

			
	 Definition
	  	Section
	Arrowhead Guarantee	  	2.3(c)
		
	Bankruptcy Code	  	3.3
		
	Bill of Sale	  	2.3(e)
		
	Breaching Party	  	12.2
		
	Calando Representatives	  	1.32

  

 8 









			
	 Definition
	  	Section
	Caltech Side Letter	  	2.2(d)
		
	Clinical Trial Investigator	  	9.2(l)
		
	Clinical Trial Site	  	9.2(k)
		
	Disclosing Party	  	1.18
		
	Escrow Agent	  	8.7(a)
		
	Escrow Agreement	  	8.7(a)
		
	Expenditure	  	5.4(c)
		
	FTE Hour	  	4.1(b)
		
	Full Access Notebooks	  	8.7(b)
		
	Initial Payment	  	5.1
		
	Inventory	  	2.1(a)
		
	Inventory Price	  	2.1(a)
		
	Irvine	  	2.1(a)
		
	Joint IP	  	7.1
		
	Lien	  	2.2(g)
		
	Losses	  	10.1
		
	Non-Breaching Party	  	12.2
		
	Non-Prosecuting Party	  	7.2(d)
		
	Note(s)	  	1.51
		
	Partial Access Notebooks	  	8.7(c)
		
	Prosecuting Party	  	7.2(d)
		
	Receiving Party	  	1.18
		
	Required Coverage	  	2.2(q)
		
	Restricted Access Notebooks	  	8.7(d)

  

 9 









			
	 Definition
	  	Section
	Royalty Payment Date	  	5.6
		
	Safety Concern	  	12.1
		
	Sale Event	  	13.1
		
	Sublicensee	  	1.55
		
	Term	  	12.1

 SECTION 2. ASSET SALE AND TRANSFER 
 2.1 Inventory. 
 (a) Calando hereby
irrevocably and unconditionally sells, transfers, conveys, assigns and delivers to Cerulean, and Cerulean hereby purchases from Calando, all right, title and interest in and to, (i) [***], for an aggregate purchase price of [***]
U.S. Dollars (US $[***]), (ii) the remaining [***] produced for [***] and having a [***], for an aggregate purchase price of [***] U.S. Dollars (US $[***]), (iii) [***]
produced for [***], to be transferred [***] to Cerulean, (iv) [***] produced for [***] and having a [***], to be transferred [***] to Cerulean, (v) [***] produced for [***] and having
a [***], to be transferred [***] to Cerulean, and (vi) the IT-101 drug substance and drug product with which [***] or its relevant Affiliate (“[***]”) is conducting stability studies, and the retain samples
of IT-101 drug substance and drug product being held by [***], each to be transferred [***] to Cerulean (such material, collectively, the “Inventory”). The total purchase price of [***] U.S. Dollars (US
$[***]) (the “Inventory Price”) shall be paid by Cerulean to Calando on the Effective Date via wire transfer of immediately available funds to an account designated by Calando. 
 (b) The Parties agree and acknowledge that Cerulean’s payment for the Inventory is in addition to the Initial Payment and is inclusive of all
excise, sales, use, transfer and other taxes and duties (if any) imposed with respect to the Inventory or its sale by any governmental authority (all of which shall be the responsibility of, and will be paid by, Calando). 
 (c) Title to and possession of the Inventory will be delivered to Cerulean, free and clear of any encumbrances, on the Effective Date in its current
location and condition at the premises of [***] or one of its Affiliates (“[***]”) in [***]. Cerulean shall be responsible for all expenses and fees related to the storage, removal and transportation of the Inventory
from and after the Effective Date, while Calando shall be responsible for all expenses and fees related to the storage, removal and transportation of the Inventory prior to the Effective Date. Risk of loss or damage, liability for, and
responsibility to insure the Inventory will pass to Cerulean on the Effective Date. 
 2.2 Calando Closing Conditions. Unless waived
by Cerulean, as of the Effective Date, Calando shall have: 
 (a) obtained the Requisite Stockholder Approval and the Requisite Debt Holder
Consent and Release; 
  

 10 








 (b) delivered to Cerulean a certificate of good standing of Calando in its jurisdiction of organization
and the various foreign jurisdictions in which it is qualified, certified charter documents and a certificate as to the incumbency of officers and the adoption of authorizing resolutions; 
 (c) provided Cerulean with a guarantee and indemnification from Arrowhead, in form and substance reasonably acceptable to Cerulean, in which Arrowhead
(i) guarantees Calando’s performance under this Agreement, (ii) makes the same representations and warranties to Cerulean as Calando makes to Cerulean under Section 9.1 or clauses (h)-(j) of Section 9.2, and
(iii) agrees to indemnify Cerulean to the same extent as Calando indemnifies Cerulean pursuant to Section 10.2 from any Losses relating to or in connection with a Third Party claim arising out of any breach by Arrowhead of its
representations or warranties as described in clause (ii), and for which indemnification Calando and Arrowhead shall be jointly and severally liable to Cerulean and the Cerulean Indemnitees (the “Arrowhead Guarantee”); 

(d) provided to Cerulean a letter agreement executed by Calando and Caltech in the form attached as Exhibit F (the “Caltech Side
Letter”); 
 (e) executed and delivered to Cerulean a bill of sale substantially in the form attached hereto as Exhibit G
(the “Bill of Sale”) and such other instruments of conveyance as Cerulean may reasonably request in order to effect the sale, transfer, conveyance and assignment to Cerulean of valid ownership to the Inventory; 
 (f) recertified the Inventory prior to the Effective Date in accordance with the testing procedures proscribed by Cerulean, and provided Cerulean with
the results thereof; 
 (g) supplied Cerulean with documentation, in form and substance reasonably acceptable to Cerulean, pursuant to which
the appropriate Affiliate of [***] acknowledges that the ownership of the Inventory has been transferred to Cerulean and releases such Inventory from any claim, liability, mortgage, pledge, security interest, encumbrance, license, charge,
encumbrance or other lien of any kind (whether arising by contract or by operation of law) (each, a “Lien”); 
 (h) supplied
Cerulean with documentation, in form and substance reasonably acceptable to Cerulean, pursuant to which the appropriate Affiliate of [***] acknowledges that the ownership of the Inventory with which it is conducting stability studies and the
ownership of the retain samples included in the Inventory have been transferred to Cerulean, releases such Inventory from all Liens and transitions to Cerulean all rights with respect to the stability studies it is conducting on the Inventory and
with respect to such retain samples; 
 (i) made available to Cerulean copies of all laboratory notebooks, raw data, summary data and reports
pertaining to the research, development or manufacture of the Licensed Product, it being understood that the terms and conditions of Section 8.7 shall apply with respect to the laboratory notebooks; 
 (j) supplied Cerulean with letters of access, in form and substance reasonably acceptable to Cerulean, addressed to all Third Party contractors and
vendors identified by Cerulean pertaining to the research, development or manufacture of the Licensed Product, it being understood that the letter of access for [***] shall be supplied subsequent to the Effective Date; 
  

 11 








 (k) supplied Cerulean with documentation, in form and substance reasonably acceptable to Cerulean,
evidencing the proper shut-down or transitioning of all sites at which Clinical Trials were conducted by Calando on IT-101 or which were contracted by Calando for the conduct of Clinical Trials on IT-101, including documentation regarding the proper
destruction or return of all IT-101 drug product from the shut-down sites, it being understood that the documentation regarding the proper shut-down of the [***] site and the destruction or return of all IT-101 drug product from the
[***] site shall be supplied subsequent to the Effective Date; 
 (l) supplied Cerulean with documentation, in form and substance
reasonably acceptable to Cerulean, evidencing the proper shut-down or transitioning of all clinical research organizations performing services in connection with the Clinical Trials for IT-101, it being understood that the documentation regarding
the proper shut-down of [***] shall be supplied subsequent to the Effective Date; 
 (m) filed with the FDA the annual report due in
May 2009 with respect to the Clinical Trials for IT-101 and provided Cerulean with a true and complete copy of all Regulatory Documentation generated on or before the Effective Date with respect to IT-101, it being understood that any Regulatory
Documentation possessed solely by Peptagen, Inc. shall be delivered subsequent to the Effective Date; 
 (n) submitted documentation,
substantially in the form of Exhibit H, to the FDA to transfer ownership of the IT-101 IND to Cerulean; and 
 (o) purchased from a
member of the Chubb Group of Insurance Companies a tail to Calando’s clinical trial insurance, in an amount of [***] combined single limit, to cover all liabilities arising from the Clinical Trials of IT-101 conducted by or on behalf of Calando
on or before the Effective Date (the “Required Coverage”), it being understood that evidence of Required Coverage, in the form of a certificate of insurance, shall be supplied subsequent to the Effective Date. 
 2.3 Cerulean Closing Conditions. As of the Effective Date, Cerulean shall have: 
 (a) delivered to Calando a certificate of good standing of Cerulean in its jurisdiction of organization and the various foreign jurisdictions in which it
is qualified and a certificate as to the incumbency of officers and the adoption of authorizing resolutions; 
 (b) executed and delivered to
Calando the CalTech Side Letter; and 
 (c) executed and delivered to Calando the Bill of Sale. 
 2.4 Calando Post-Closing Covenants. As promptly as practicable after the Effective Date, at the expense of Calando, Calando shall: 
 (a) deliver to Cerulean a final report for the Phase 1 Clinical Trial for IT-101 which is fully compliant with all applicable laws and regulations and
otherwise meets industry standards for reports of such type and which is in a format for filing with the FDA; and 
 (b) supply Cerulean with
all clinical data from the [***] site, with the documentation regarding the proper shut-down of PharmaLinkFHI, Inc. and the [***] site, with the documentation regarding the destruction or return of all IT-101 drug product from the [***] site, with
the letter of access for [***], and with any Regulatory Documentation obtained by Calando from [***] subsequent to the Effective Date. 
  

 12 








 2.5 Regulatory Documentation. From and after the Effective Date, Cerulean shall own, and Calando
hereby assigns to Cerulean all right, title and interest in and to, all Regulatory Documentation regarding the Licensed Product and all intellectual property rights therein. 
 2.6 Non-Assumption of Liabilities. Notwithstanding anything to the contrary, Cerulean shall not assume, or become responsible for, and Calando
shall remain responsible for, the Calando Liabilities. 
 SECTION 3. LICENSES 
 3.1 Grant to Cerulean. Calando hereby grants to Cerulean an exclusive (even as to Calando, but subject to Section 12.2(b)), transferable (as
permitted pursuant to Section 13.1), irrevocable and perpetual (subject to each Party’s termination rights in Section 12), royalty-bearing, worldwide license, with the right to grant sublicenses, under the Licensed Patent Rights and
under all intellectual property rights in the Licensed Know-How, solely in order to (a) research, develop, make, have made, use, market, offer to sell, distribute, sell and import Licensed Products in the Field, and (b) use, copy, modify
and distribute the Licensed Know-How for such purposes. 
 3.2 Sublicenses. All sublicenses granted pursuant to Section 3.1 shall
be consistent with the terms and conditions of this Agreement and Cerulean shall incorporate terms and conditions into its sublicense agreements sufficient to enable Cerulean to comply with this Agreement. Cerulean shall furnish Calando with a copy
of each executed sublicense agreement within ten (10) business days after its execution. 
 3.3 Section 365(n) of the Bankruptcy
Code. All rights and licenses granted under or pursuant to any section of this Agreement are and shall otherwise be deemed to be for purposes of Section 365(n) of the Bankruptcy Code licenses of rights of “intellectual property”
as defined in Section 101(35A) of the United States Bankruptcy Code (Title 11, U.S.C.), as amended (the “Bankruptcy Code”). The Parties shall retain and may fully exercise all of their respective rights and elections under the
Bankruptcy Code. Upon the bankruptcy of a Party, the non-bankrupt Party shall further be entitled to a complete duplicate of, or complete access to, any such intellectual property, and such, if not already in its possession, shall be promptly
delivered to the non-bankrupt Party, unless the bankrupt Party elects to continue, and continues, to perform all of its obligations under this Agreement. 
 3.4 Patent Marking. Cerulean shall mark the appropriate U.S. patent number(s) on Licensed Products made or sold in the United States in accordance with all applicable government laws, rules and regulations.

 SECTION 4. POST-CLOSING ASSISTANCE AND COVENANTS 
 4.1 Technology Transfer. 
 (a) Within the first twelve (12) months following the Effective Date,
Calando shall, and shall cause its employees to provide to Cerulean, upon Cerulean’s request, such scientific, technical and other assistance as is reasonably necessary for Cerulean to exploit the Licensed Know-How; provided,
however, that this Section 4.1(a) shall not require Calando to 
  

 13 








 maintain employment of any employees; provided, further, that Calando shall use commercially reasonable
efforts to assist Cerulean in entering into employment or consulting arrangements (at Cerulean’s sole cost) with any former employees of Calando. In addition, Calando shall reasonably assist Cerulean in interacting with Calando’s Third
Party contractors and vendors to facilitate Cerulean’s ability to develop the Licensed Product and exploit the Licensed Know-How; provided, that Calando makes no representations or warranties as to such Third Party
contractors’ or vendors’ intentions to conduct business with Cerulean following the Effective Date. To the extent that Cerulean hires or engages the services of any former employee of Calando or any Third Party contractor or vendor of
Calando for purposes contemplated under this Agreement, Calando hereby waives any obligations of confidentiality or non-use or any non-competition restrictions imposed on such employees, contractors or vendors to the extent that they pertain to the
Licensed Product or use of the Cyclodextrin System in connection with the Licensed Product. 
 (b) Cerulean shall reimburse Calando
(i) for the assistance described in Section 4.1(a) at the rate of [***] U.S. Dollars (US $[***]) for each hour of scientific, technical or other work in providing such assistance (each, an “FTE Hour”)
and (ii) for all reasonable out-of-pocket expenses incurred by Calando in providing such assistance, to the extent such assistance and expenses have been approved by Cerulean in writing in advance of incurrence. Within thirty (30) days
after the end of each calendar month during such twelve (12) month period, Calando shall provide to Cerulean a report of the number of FTE Hours actually devoted, and the expenses actually incurred, by Calando for such assistance during such
just-ended calendar month, and an invoice for the amount to be reimbursed by Cerulean as provided hereunder. Cerulean shall pay such invoice within fifteen (15) days after receipt. For the sake of clarity, there shall be no double payments for
any assistance which may be provided under both this Agreement and the Platform Agreement. 
 (c) Calando shall keep true and accurate books
of accounts and other records containing all information and data which may be necessary to ascertain and verify the amounts payable under this Section 4.1. During the first eighteen (18) months after the Effective Date, Cerulean shall
have a one-time right to have an independent certified public accountant inspect such books and records of Calando. Any such independent certified accountant shall be reasonably acceptable to Calando, shall execute a standard form of confidentiality
agreement with Calando, and shall be permitted to share with Cerulean solely its findings with respect to the accuracy of the amounts reported as payable under this Section 4.1. 
 4.2 Caltech Agreements. 
 (a) Calando
shall not amend, restate, alter, waive or otherwise change any of the terms and conditions of the Caltech Agreement or Caltech Side Letter without the prior written approval of Cerulean, which approval shall not be unreasonably withheld, conditioned
or delayed. Calando shall provide Cerulean with a copy of any proposed or executed amendment, restatement, alteration, waiver or other change of the terms and conditions of the Caltech Agreement or Caltech Side Letter. Further, Calando shall not
assign (other than in connection with a Sale Event) or terminate the Caltech Agreement or Caltech Side Letter without the prior written approval of Cerulean, which approval shall not be unreasonably withheld, conditioned or delayed. 
 (b) Calando shall use commercially reasonable efforts to satisfy all of its obligations under and to take all steps necessary to maintain in full force
and effect the Caltech Agreement or Caltech Side Letter. Calando shall provide Cerulean with written notice of any claim of a breach under, or any threat or notice of termination of, the Caltech Agreement or Caltech Side Letter. 
  

 14 








 4.3 Further Assurances. At any time and from time to time hereafter, each Party at the other
Party’s request and without further consideration, shall execute and deliver, or cause to be duly executed and delivered (including by its Affiliates and employees), such further instruments and do and cause to be done such further acts and
things, including the filing of such assignments, agreements, documents and instruments, as may be necessary or as the requesting Party may reasonably request in connection with this Agreement or to carry out more effectively the provisions and
purposes hereof, or to better assure and confirm the rights and remedies of the Parties under this Agreement, including to more effectively transfer, convey and assign to Cerulean, and to confirm Cerulean’s title to, all of the Inventory, to
put Cerulean in actual possession and control thereof, to assist Cerulean in exercising all rights with respect thereto and to carry out the purpose and intent of this Agreement. Other than those obligations expressly set forth herein, Cerulean
shall not assume or agree to perform, pay or discharge, and Calando shall remain unconditionally liable, for the Calando Liabilities. 
 SECTION 5. FEES AND ROYALTIES 
 5.1 Fees. Cerulean shall pay Calando a one-time, non-refundable, non-creditable
purchase and license fee in the amount of [***] U.S. Dollars (US $[***]) (the “Initial Payment”). In addition, Cerulean shall reimburse Calando for [***] U.S. Dollars ($[***]), which amount represents
[***] percent ([***]%) of the cost of the Required Coverage. The foregoing amounts shall be distributed as follows: (a) [***] U.S. Dollars and [***] Cents (US $[***]) shall be paid by Cerulean directly to the
applicable Third Parties as set forth in Exhibit I, on behalf of Calando, on the Effective Date; (b) [***] U.S. Dollars and [***] Cents (US $[***]) shall be paid by Cerulean to Calando via wire transfer of
immediately available funds to an account designated by Calando, on the Effective Date; and (c) [***] U.S. Dollars (US $[***]) shall be paid by Cerulean to Calando via wire transfer of immediately available funds to an account
designated by Calando within ten (10) days of Calando’s having fulfilled the post-closing conditions set forth in Section 2.4. 
 5.2 Development Milestones. 
 (a) If the Licensed Product is developed by Cerulean or an Affiliate of Cerulean and reaches
the following development milestones, Cerulean shall pay the applicable non-refundable milestone payment set forth below, subject to Section 5.2(b), within thirty (30) days of the occurrence of such event to Calando via wire transfer of
immediately available funds to an account designated by Calando: 
  

			
	 Milestone Event:
	  	 Milestone Payment:

	(i) Initiation (first dosing of the first patient) of the first Phase 3 Clinical Trial	  	[***] U.S. Dollars (US $[***])
		
	(ii) The filing of the first NDA with any Regulatory Authority	  	[***] U.S. Dollars (US $[***])
		
	(iii) First Commercial Sale in any country	  	[***] U.S. Dollars (US $[***])

  

 15 








 (b) Such milestone payments shall be made only if, upon the occurrence of such milestone event, a Valid
Claim of a Collective Patent Right exists in any country of the world. Each such payment shall be made no more than once. All development milestone payments made with respect to the Licensed Product shall be fully credited to all royalties due under
Section 5.5 with respect to the Licensed Product. 
 5.3 Sales Milestones. 
 (a) If the Licensed Product is developed by Cerulean or an Affiliate of Cerulean and reaches the following sales thresholds, Cerulean shall pay the
applicable non-refundable, non-creditable milestone payment set forth below, subject to Section 5.3(b), within thirty (30) days after the occurrence of such event to Calando via wire transfer of immediately available funds to an account
designated by Calando: 
  

			
	 Milestone Event:
	  	 Milestone Payment:

	(i) Annual Net Sales of [***] U.S. Dollars (US $[***])	  	[***] U.S. Dollars (US $[***])
		
	 (ii) Annual Net Sales of [***] U.S. Dollars (US $[***])
	  	[***] U.S. Dollars (US $[***])

 (b) Such milestone payments shall be made only if, upon the occurrence of such milestone event, a
Valid Claim of a Collective Patent Right exists in any country of the world. Each such payment shall be made no more than once. 
 5.4
Sublicense Income. 
 (a) With respect to Licensed Product developed and sold by a Sublicensee, Cerulean shall pay to Calando, subject
to Section 5.4(b), a percentage of all Sublicense Income received from such Sublicensee (on a Sublicensee-by-Sublicensee basis), which percentage shall be determined in accordance with the table below depending on the state of development of
the Licensed Product at the time that Cerulean first provides or receives draft terms of a sublicensing arrangement with such Sublicensee; provided, however, that, if discussions between Cerulean and such Sublicensee terminate and
later restart at a different state of development, then the percentage shall be based on the later state of development of the Licensed Product: 
  

			
	 Development State:
	  	 Percentage of
 Sublicense Income:

	(i) Prior to the initiation (first dosing of the first patient) of a Phase 3 Clinical Trial and Cerulean’s Expenditures are less than US $[***] (exclusive of the Inventory Price and
the Initial Payment)	  	[***]%
		
	(ii) Following the initiation (first dosing of the first patient) of a Phase 3 Clinical Trial, but before Regulatory Approval in any of the United States, Japan or any European country, and
Cerulean’s Expenditures are less than $[***] (exclusive of the Inventory Price, the Initial Payment and any milestones paid to Calando pursuant to Section 5.2)	  	[***]%

  

 16 









			
	 Development State:
	  	Percentage of
Sublicense Income:
	(iii) Prior to Regulatory Approval in any of the United States, Japan or any European country and Cerulean’s Expenditures are at least US $[***] but less than US $[***]
(exclusive of the Inventory Price, the Initial Payment and any milestones paid to Calando pursuant to Section 5.2)	  	[***]%
		
	(iv) Prior to Regulatory Approval in any of the United States, Japan or any European country and Cerulean’s Expenditures are at least US $[***] (exclusive of the Inventory Price, the
Initial Payment and any milestones paid to Calando pursuant to Section 5.2)	  	[***]%
		
	(v) Following Regulatory Approval in any of the United States, Japan or any European country regardless of Cerulean’s Expenditures	  	[***]%

 (b) Such payments shall be made only if, at the time of Cerulean’s or its Affiliate’s
receipt of Sublicense Income, a Valid Claim of a Collective Patent Right exists in any country of the world. The percentage of Sublicense Income due Calando for earned royalties (but not for upfront payments, milestones or maintenance fees) will be
capped at the royalty rates under Section 5.5 that would apply if such sales were made by Cerulean or an Affiliate of Cerulean. 
 (c)
“Expenditure” means the fully-burdened cost and all out-of-pocket costs incurred by Cerulean and its Affiliates in connection with all activities associated with the Licensed Product during their development of the Licensed Product.
For purposes of calculating the fully burdened cost of Cerulean and its Affiliates, Cerulean shall use an annual FTE rate of $[***] (for 1800 hours of full-time equivalent work), which rate shall be subject to increase annually based on the
percentage increase in the Consumer Price Index. For purposes of clarity, in no event shall Cerulean be entitled to count as part of its Expenditures diligence or transaction costs (including legal fees) expended on, or with respect to, IT-101 prior
to the Effective Date. 
 5.5 Royalties. 
 (a) Base Rate. 
 (i) For each Licensed Product sold by Cerulean or an Affiliate of Cerulean, Cerulean
shall pay to Calando (subject to Sections 5.2(b), 5.5(b), 5.5(c) and 5.5(d)) the following tiered earned royalties on Annual Net Sales of each Licensed Product whose manufacture, use or sale, at the time of sale and in the country of sale, is, or
would be if such manufacture or use occurred in the country of sale, Covered by a Valid Claim of a Collective Patent Right: 
  

			
	 Annual Net Sales Tiers:
	  	Royalty Rate:
	 The portion of Annual Net Sales which is less than or equal to US $[***]
	  	[***]%
		
	 The portion of Annual Net Sales which is greater than US $[***]
	  	[***]%

  

 17 








 (ii) For each Licensed Product sold by Cerulean or an Affiliate of Cerulean, Cerulean shall pay to
Calando (subject to Sections 5.2(b), 5.5(b), 5.5(c) and 5.5(d)) the following tiered earned royalties on Annual Net Sales of each Licensed Product whose manufacture, use or sale, at the time of sale and in the country of sale, is not, and would not
be if such manufacture or use occurred in the country of sale, Covered by a Valid Claim of a Collective Patent Right: 
  

			
	 Annual Net Sales Tiers:
	  	Royalty Rate:
	 The portion of Annual Net Sales which is less than or equal to US $[***]
	  	[***]%
		
	 The portion of Annual Net Sales which is greater than US $[***]
	  	[***]%

 (b) Royalty Term. 
 (i) Royalties on the Licensed Product whose manufacture, use or sale, at the time of sale and in the country of sale, is, or would be if such manufacture
or use occurred in the country of sale, Covered by a Valid Claim of a Collective Patent Right shall be payable until the expiration of such Valid Claim. 
 (ii) Royalties on the Licensed Product whose manufacture, use or sale, at the time of sale and in the country of sale, is not, and would not be if such manufacture or use occurred in the country of sale, Covered by a
Valid Claim of a Collective Patent Right shall be payable if such sale occurs within the first ten (10) years after the First Commercial Sale of the Licensed Product in such country; provided, however, that, at the time of such
manufacture, use or sale, a Valid Claim of a Collective Patent Right exists in any country of the world. 
 (iii) Once the royalty
obligations hereunder end with respect to the Licensed Product in a country of sale, Cerulean shall have a fully paid-up, non-exclusive, perpetual license, under the Licensed Patent Rights, and under all intellectual property rights in the Licensed
Know-How, to research, develop, make, have made, use, market, offer to sell, distribute, sell and import the Licensed Product in any country in order to sell the Licensed Product in the Field in such country and to use, copy, modify and distribute
the Licensed Know-How for such purposes. 
 (c) The obligation to pay royalties shall be imposed only once, at the point of the first sale,
with respect to a particular unit of Licensed Product. 
 (d) Cerulean shall be entitled to deduct from the royalty payments it makes
pursuant to Section 5.5(a) with respect to the Licensed Product [***] percent ([***]%) of Required Third Party Payments with respect to the Licensed Product; provided, that, in no event shall a deduction under this
Section 5.5(d) reduce any royalty payment payable by Cerulean pursuant to Section 5.5(a) by more than [***] percent ([***]%). Cerulean shall be entitled to carry forward any unused amounts against future royalty payments
payable by Cerulean hereunder with respect to the Licensed Product, until such unused amounts are fully offset. 
  

 18 








 (e) Calando shall remain solely responsible for any payments owed under the Caltech Agreement.

 5.6 Reports and Payment. Commencing with the calendar quarter in which the First Commercial Sale of a Licensed Product occurs in
any country in the world and continuing during the Term, Cerulean shall deliver to Calando, within sixty (60) days after the end of each calendar quarter (the “Royalty Payment Date”), (a) a written report showing
Cerulean’s computation of Sublicense Income due under this Agreement for such calendar quarter, (b) a written report showing Cerulean’s computation of royalties due under this Agreement for such calendar quarter on a
country-by-country basis and (c) payment of the Sublicense Income and royalties shown to be due under this Agreement for such calendar quarter via wire transfer of immediately available funds to an account designated by Calando. With respect to
sales of Licensed Products invoiced in United States Dollars, the sales and royalties payable shall be expressed in United States Dollars. With respect to sales of Licensed Products invoiced in a currency other than United States Dollars, the sales
and royalties payable shall be expressed in their United States Dollar equivalent calculated using the applicable conversion rates for buying United States Dollars published by The Wall Street Journal on the last business day of the calendar
quarter to which the royalty report relates. All Sublicense Income and royalty payments shall be made in United States Dollars. 
 5.7
Right to Setoff. If Calando and/or Arrowhead fails to indemnify a Cerulean Indemnittee as contractually provided for in Section 10.2, then Cerulean may, at its option and upon written notice to Calando, setoff such amount from any
amounts owed by Cerulean to Calando pursuant to Sections 5.2, 5.3, 5.4 or 5.5 of this Agreement. 
 5.8 Tax Withholding. Cerulean
shall use reasonable and legal efforts to reduce tax withholding payments to be made to Calando. Notwithstanding the foregoing, if Cerulean concludes that tax withholdings under the laws of any country are required with respect to payments to
Calando, Cerulean shall withhold the required amount and pay it to the appropriate governmental authority. In any such case, Cerulean shall promptly provide Calando with original receipts or other evidence reasonably desirable and sufficient to
allow Calando to document such tax withholdings for purposes of claiming foreign tax credits and similar benefits. 
 5.9 Records.
Cerulean shall keep, and shall require its Affiliates and Sublicensees to keep, true and accurate books of accounts and other records containing all information and data which may be necessary to ascertain and verify the royalties and other amounts
payable by Cerulean under this Agreement. During the Term and for a period of three (3) years thereafter, Calando shall have the right from time to time (not to exceed once during each calendar year) (a) to have an independent certified
public accountant inspect such books and records of Cerulean and its Affiliates and (b) to require that Cerulean have an independent certified public accountant inspect such books and records of the Sublicensees. Any such independent certified
public accountant shall be reasonably acceptable to Cerulean, shall execute a standard form of confidentiality agreement with Cerulean, shall be permitted to share with Cerulean its findings, and shall be permitted to share with Calando solely its
findings with respect to the accuracy of the amounts reported as payable under this Agreement. If such audit determines that the royalties paid to Calando pursuant to Section 5.5(a) for any such audited period were understated, then Cerulean
shall, within ten (10) days of receipt of the audit report, pay to Calando the entirety of such understated amount plus interest accruing from the Royalty Payment Date until the date that 
  

 19 








 such understated amount is paid at an interest rate equal to the lesser of (i) ten percent (10%) per annum or
(ii) the highest interest rate allowable by law. If such audit determines that the royalties paid to Calando pursuant to Section 5.5 for any such audited period were understated by an amount equal to or greater than five percent
(5%) of what was owed, then Cerulean shall) reimburse Calando for any reasonable out-of-pocket costs of such audit paid by Calando. 
 SECTION 6. DILIGENCE 
 6.1 Diligence. Cerulean, through itself, its Affiliates or sublicensees, shall use
[***]. In addition, if, at any time prior to the [***], then Cerulean (or its successor, as applicable), together with its Affiliates and sublicensees, shall [***], during each Diligence Period; provided, however,
that, in lieu of such [***]. Such amount shall be pro-rated for any Diligence Period which is less than twelve months in length. “Diligence Period” means the [***]. 
 6.2 Performance Reports. Cerulean agrees to provide annual performance reports to Calando within thirty (30) calendar days of a written
request by Calando which shall be no more frequent than once every twelve (12) months. These performance reports shall describe all research and development efforts for the Licensed Product since the last performance report. After the date of
First Commercial Sale of the Licensed Product in any of the European Union, United States or Japan, such annual reports shall no longer be required. 
 6.3 Conformity with Caltech Agreement. If, and to the extent, that Caltech, pursuant to Section 5.2 of the Caltech Agreement, requires Calando to report on the progress of introducing commercial Licensed
Products in the United States, Calando shall promptly (but in any event within five (5) business days) report such requirement to Cerulean and Cerulean shall promptly (within thirty (30) days thereafter) provide a written report thereof to
Calando and Calando shall promptly (but in any event within five (5) business days) provide such report to Caltech. 
 6.4 Compliance
with Laws. Each Party shall, and shall ensure that its Affiliates and sublicensees shall, comply with all applicable laws in exercising their rights and fulfilling their obligations under this Agreement. 
 SECTION 7. INTELLECTUAL PROPERTY 
 7.1
Ownership. As between the Parties, (a) all Know-How developed, conceived or reduced to practice after the Effective Date solely by employees and consultants of Cerulean or its Affiliates, and all intellectual property rights in the
foregoing, shall be owned solely by Cerulean, and (b) all Know-How developed, conceived or reduced to practice after the Effective Date solely by employees and consultants of Calando or its Affiliates, and all intellectual property rights in
the foregoing, shall be owned solely by Calando. While the Parties do not anticipate that any Know-How will be jointly developed, if any Know-How is developed, conceived or reduced to practice after the Effective Date jointly by employees and
consultants of Cerulean or its Affiliates, on the one hand, and Calando or its Affiliates, on the other hand, such Know-How and all intellectual property rights therein (such Know-How and intellectual property rights, collectively, “Joint
IP”), shall be owned jointly by Cerulean and Calando, on the basis of an undivided interest. Subject to the licenses granted to Cerulean pursuant to Section 3.1 and pursuant to the Platform Agreement, each Party shall have the right to
fully exploit the Joint IP, and to sublicense such Party’s rights under the Joint IP, without a duty to account to the other Party. If any patentable Joint IP is conceived or reduced to practice, the Parties shall negotiate in good faith
reasonable rights and responsibilities of the Parties to prosecute and enforce such Joint IP. Inventorship, for the purposes of this Section 7.1, shall be determined by the Parties in good faith in accordance with United States patent laws.

  

 20 








 7.2 Patent Prosecution. 
 (a) Assigned Patent Rights. Cerulean shall have the sole right, at its own expense and in its own name, to prepare, file, prosecute and maintain
the Assigned Patent Rights. If Cerulean determines to discontinue the prosecution or maintenance of any patent application or patent within such Assigned Patent Rights, Cerulean shall promptly notify Calando, sufficiently in advance of any deadlines
to ensure that no rights with respect thereto are lost, and thereupon, Calando shall have the right, at its own expense, to prosecute and maintain any such Patent Right. 
 (b) RNAi Patent Rights. Calando shall have the sole right, at its own expense and in its own name, to prepare, file, prosecute and maintain the RNAi Patent Rights. 
 (c) Caltech Patent Rights. The Parties agree and acknowledge that, with respect to the Caltech Joint Patent Rights and the Caltech Sole Patent
Rights, as set forth in the Caltech Agreement, Caltech has the right to prosecute such Patent Rights, Calando has the right to comment on such prosecution and Calando pays the patent costs thereof, but that: 
 (i) Calando shall use reasonable efforts to cause Caltech to promptly provide Calando with copies of all material correspondence received from any patent
counsel or patent authority pertaining to such Patent Rights; 
 (ii) Calando shall promptly provide Cerulean with copies of all
correspondence received by Calando from Caltech from any patent counsel or patent authority pertaining to such Patent Rights; 
 (iii)
Calando shall provide Cerulean, sufficiently in advance of any deadline for Cerulean to comment, with copies of all patent applications and other submissions and correspondence with any patent counsel or patent authority pertaining to such Patent
Rights, and shall use reasonable efforts to ensure that Caltech gives due consideration to Cerulean’s comments; and 
 (iv) in the
event of the bankruptcy or other insolvency of Calando or a termination, for any reason, of the Caltech Agreement, as between the Parties, the provisions of the Caltech Side Letter shall supersede any conflicting provisions of this
Section 7.2(c) and the Caltech Agreement. 
 (d) Other Licensed Patent Rights. Calando shall have the initial right, at its own
expense and in its own name, to prepare, file, prosecute and maintain any Licensed Patent Rights other than the Caltech Joint Patent Rights, Caltech Sole Patent Rights and RNAi Patent Rights. If Calando determines not to prepare or file any patent
application covering any Licensed Know-How or determines to discontinue the prosecution or maintenance of any patent application or patent within such Licensed Patent Rights, Calando shall promptly notify Cerulean, sufficiently in advance of any
deadlines to ensure that no rights with respect thereto are lost, and thereupon, Cerulean shall have the right, at its own expense, to prepare, file, prosecute and maintain any such Patent Right. With respect to the preparation, filing, prosecution
and maintenance of such Licensed Patent Rights: 
  

 21 








 (i) the Party not preparing, filing, prosecuting or maintaining such patent or patent application (the
“Non-Prosecuting Party”) shall, at the reasonable request of the other Party (the “Prosecuting Party”), assist and cooperate in the filing, prosecution and maintenance of such Patent Rights; 
 (ii) the Prosecuting Party shall provide the Non-Prosecuting Party, sufficiently in advance of any deadline for the Non-Prosecuting Party to comment,
with copies of all patent applications and other submissions and correspondence with any patent counsel or patent authority pertaining to such Patent Rights; 
 (iii) the Prosecuting Party shall give due consideration to the Non-Prosecuting Party’s comments, but the Prosecuting Party shall have the final say in determining whether or not to incorporate such comments;

 (iv) each Party shall promptly provide the other with copies of all correspondence received from any patent counsel or patent authority
pertaining to such Patent Rights; and 
 (v) if Cerulean is preparing, filing, prosecuting or maintaining Licensed Patent Rights, Cerulean
may fully credit any out-of-pocket expenses incurred by Cerulean in connection therewith against any other payments due by Cerulean hereunder. 
 7.3 Enforcement. 
 (a) Notice. Each Party shall promptly (but within no more than five (5) days) report in
writing to the other Party during the Term any suspected infringement of the Collective Patent Rights (including any “patent certification” filed in the United States under 21 U.S.C. §355(b)(2) or 21 U.S.C. §355(j)(2) or similar
provisions in other jurisdictions), any declaratory judgment, opposition, or similar action alleging the invalidity, unenforceability or non-infringement of the Collective Patent Rights, or any suspected unauthorized use or misappropriation of any
Licensed Know-How or of the other Party’s Confidential Information, of which it becomes aware, and shall provide the other Party with all available evidence supporting such suspected infringement, action or unauthorized use or misappropriation.

 (b) Enforcement of Assigned Patent Rights. Cerulean shall have the sole right to initiate an appropriate suit anywhere in the world
against any Third Party who at any time is suspected of infringing all or any portion of the Assigned Patent Rights. 
 (c) Enforcement of
RNAi Patent Rights. Calando shall have the sole right to initiate an appropriate suit anywhere in the world against any Third Party who at any time is suspected of infringing all or any portion of the RNAi Patent Rights. 
 (d) Enforcement of Licensed Patent Rights other than RNAi Patent Rights. 
 (i) Cerulean shall have the first right to initiate an appropriate suit anywhere in the world against any Third Party who at any time is suspected of
infringing all or any portion of the Licensed Patent Rights other than the RNAi Patent Rights, or using without proper authorization all or any portion of the Licensed Know-How, by researching, developing, making, having made, using, marketing,
offering to sell, distributing, selling or importing any product that falls within the scope of the definition of “Licensed Product”. Calando shall join as a party to any such suit brought by Cerulean, if requested by Cerulean, but shall
be under no 
  

 22 








 obligation to participate except to the extent that such participation is required as the result of being a named party
to the suit. Upon Cerulean’s request, Calando shall provide reasonable assistance to Cerulean in connection therewith at no charge to Cerulean except for reimbursement of Calando’s reasonable out-of-pocket expenses (including reasonable
attorneys’ fees) incurred in rendering such assistance. Any recoveries resulting from such action (whether in the form of damages, royalties, settlement payments or otherwise) shall first be applied to reimburse Cerulean for all out-of-pocket
expenses incurred in connection with such proceeding (and any out-of-pocket expenses of Calando paid by Cerulean) and (A) to the extent that the remaining recovery represents lost profits, such remaining recovery shall be retained by Cerulean,
with Calando entitled to receive an amount equal to the royalties that would have been due Calando on sales of the relevant Licensed Product lost by Cerulean as a result of the infringement and (B) to the extent that the remaining recovery
represents punitive or other damages, Cerulean shall be entitled to [***] of such remaining recovery and Calando shall be entitled to [***] of such remaining recovery. 
 (ii) If, within one hundred eighty (180) days after notification of an infringement of the Licensed Patent Rights with respect to which Cerulean
would have the first right to bring suit as described in Section 7.3(d)(i), Cerulean has not been successful in persuading the alleged infringer to desist and is not diligently pursuing an infringement action or suit, or has notified Calando of
its intent not to bring action or suit against the alleged infringer, then Caltech or Calando may institute an action or suit against such Third Party, in accordance with their rights of priority under Sections 6.1 and 6.2 of the Caltech Agreement,
subject to the following if Calando institutes such action or suit: 
 (A) Prior to taking any action, Calando shall confer with Cerulean and
give due consideration to Cerulean’s reasons for not pursuing such alleged infringer. 
 (B) The action or suit shall be brought in the
name of Caltech and/or Calando and Calando shall bear the entire cost of such action or suit. Calando shall promptly provide Cerulean with copies of all litigation pleadings and other documents submitted to the court. 
 (C) With respect to any consideration received by Calando in connection with such action or suit, Calando shall first be entitled to deduct its
litigation expenses and legal fees (including any incurred as part of an indemnification of Cerulean). All remaining recovery shall be [***]. 
 (D) If it shall be necessary for Calando to join Cerulean as a party to an action or suit because Cerulean constitutes a legally indispensable party, Calando shall have the right to so join Cerulean; provided,
that Calando indemnifies Cerulean for all outside costs and expenses (including reasonable attorneys fees) thereby incurred by Cerulean. 
 (iii) Calando shall have the sole right to initiate an appropriate suit anywhere in the world against any Third Party who at any time is suspected of infringing all or any portion of the Licensed Patent Rights other than the RNAi Patent
Rights, or using without proper authorization all or any portion of the Licensed Know-How, by researching, developing, making, having made, using, marketing, offering to sell, distributing, selling or importing any product that falls within the
scope of the definition of “Retained Product” (as defined in the Platform Agreement). 
  

 23 








 (iv) The Party enforcing such Licensed Patent Rights or Licensed Know-How pursuant to
Section 7.3(d)(i), (ii) or (iii) shall have the sole and exclusive right to select counsel for any such suit referred and shall, except as provided herein, pay all expenses of the suit, including attorneys’ fees and court costs.
Neither Party shall settle any suit described in this Section 7.3 involving rights of the other Party without obtaining the prior written consent of such other Party, which consent shall not be unreasonably withheld. 
 7.4 Power of Attorney. Calando hereby constitutes and appoints the President of Cerulean with full power of substitution, the true and lawful
attorney-in-fact and agent of Calando, to execute, acknowledge, verify, swear to, deliver, record and file, in Calando’s or its assignee’s name, place and stead, all in accordance with the terms of this Agreement, all instruments,
documents and certificates which may from time to time be required by the laws of the governmental authority to prosecute, maintain and enforce the Licensed Patent Rights other than the RNAi Patent Rights, and to prepare and file any patent
applications covering Licensed Know-How, in each case to the extent Calando or its assignee has such right pursuant to this Section 7. The power of attorney granted herein will be deemed to be coupled with an interest, will survive and not be
affected by the dissolution, bankruptcy or legal disability of Calando and will extend to its successors and assigns. If required, Calando shall execute and deliver to Cerulean within five (5) days after the receipt of a request therefor, such
further designations, powers of attorney or other instruments as Cerulean will reasonably deem necessary for the purposes described in this Section 7.4. 
 7.5 Claimed Infringement. If a Third Party at any time provides written notice of a claim, or brings an action, suit or proceeding, against either Party or any of its Affiliates or sublicensees, claiming
infringement of such Third Party’s Patent Rights or unauthorized use or misappropriation of such Third Party’s Know-How, arising out of the research, development, making, having made, use, marketing, offering to sell, distribution, sale or
importation of the Licensed Product, such Party shall promptly notify the other Party of the claim or the commencement of such action, suit or proceeding, enclosing a copy of the claim and all papers served and such Party shall have the sole right
and responsibility to take any action it deems appropriate with respect such claim, action, suit or proceeding. 
 SECTION 8. CONFIDENTIAL
INFORMATION 
 8.1 Treatment of Confidential Information. Each Receiving Party shall maintain in confidence the Confidential
Information of the Disclosing Party and shall not disclose, divulge or otherwise communicate such Confidential Information to others, or use it for any purpose, except to exercise its rights or fulfill its obligations under this Agreement. Each
Receiving Party shall exercise every reasonable precaution to prevent and restrain the unauthorized disclosure of such Confidential Information by any of its directors, officers, employees, consultants, subcontractors, sublicensees or agents.

 8.2 Release from Restrictions. The provisions of Section 8.1 shall not apply to any Confidential Information of the Disclosing
Party which: 
 (a) was known or used by the Receiving Party or any of its Affiliates prior to its date of disclosure to the Receiving Party,
as demonstrated by competent evidence of the Receiving Party; 
  

 24 








 (b) either before or after the date of the disclosure to the Receiving Party is lawfully disclosed to the
Receiving Party or any of its Affiliates by a Third Party rightfully in possession of, and with the right to disclose, such Confidential Information; 
 (c) either before or after the date of the disclosure to the Receiving Party becomes published or generally known to the public through no fault or omission on the part of the Receiving Party or its Affiliates;

 (d) is required to be disclosed by the Receiving Party to comply with applicable laws or regulations, to defend or prosecute litigation or
arbitration, to file for patent protection as permitted hereunder or to file for Regulatory Approval as permitted hereunder; provided, however, that (i) with respect to a disclosure to comply with laws or regulations or to defend
or prosecute litigation or arbitration, then, to the extent permitted by law, the Receiving Party shall provide the Disclosing Party with prompt notice of any such requirement, and (ii) with respect to any disclosure under this clause (d),
then, where available, the Receiving Party shall take reasonable and lawful actions to avoid and/or minimize the degree of such disclosure; or 
 (e) is independently developed by the Receiving Party or any of its Affiliates without reference to the Confidential Information of the Disclosing Party; 
 provided, however, that Calando may not rely on the provisions of Section 8.2(a) or (b) with respect to the Assigned IP. 
 8.3 Permitted Disclosure. The Receiving Party may provide the Disclosing Party’s Confidential Information to the directors, employees, consultants and advisors of the Receiving Party and its Affiliates,
and to its then-current and potential licensees who have a need to know such Confidential Information for purposes of the Receiving Party granting licenses or sublicenses under Collective Patent Rights or Licensed Know-How as permitted herein;
provided, that such persons shall (a) execute or have executed an agreement in reasonable form whereby they agree to be bound by an obligation, or (b) be bound by ethical or fiduciary obligations, in each case to maintain the
confidentiality of the Disclosing Party’s Confidential Information at least to the same extent as if they were parties hereto. 
 8.4
Publicity. No Party shall have the right to make any public announcements with respect to this Agreement, nor publicly disclose the terms of this Agreement, without the prior written consent of the other Party, except as follows: 

(a) On the first business day following the execution of this Agreement, each Party shall issue its press release attached hereto as Exhibit J.

 (b) Each Party may disclose the terms of this Agreement to the extent such disclosure is required by law (including by rules or
regulations of any securities exchange or NASDAQ) or to defend or prosecute litigation or arbitration; provided, that, prior to such disclosure, to the extent permitted by law or such rules or regulations, the disclosing Party promptly
notifies the other Party of such requirement and gives such other Party an opportunity to comment on the disclosure to be made, the disclosing Party furnishes only those terms of this Agreement that the disclosing Party is legally required to
furnish and the disclosing Party requests, and use reasonable efforts to obtain, confidential treatment of financial and other commercially sensitive terms. 
  

 25 








 (c) Each Party may make subsequent disclosures of information which has been previously publicly
disclosed in accordance with this Agreement. 
 (d) Calando may disclose this Agreement to (i) Calando’s then-current and potential
Third Party licensors or licensees of the Collective Patent Rights, and (ii) Calando’s then-current and potential investors and acquirers; provided, that such persons are bound to maintain the confidentiality of this Agreement to
the same extent as if they were parties hereto and Calando shall not disclose the financial and other commercially sensitive terms of this Agreement to any licensee outside the Field. 
 (e) Cerulean may disclose this Agreement to (i) Cerulean’s then-current and potential licensors or licensees of the Collective Patent Rights,
and (ii) Cerulean’s then-current and potential investors and acquirers; provided, that such persons are bound to maintain the confidentiality of this Agreement to the same extent as if they were parties hereto. 
 (f) From and after the Effective Date, Cerulean shall have the right to make and control all disclosures regarding Licensed Products. 
 8.5 Enforcement. The provisions of Section 8 of this Agreement are necessary for the protection of the business and goodwill of the Parties
and are considered by the Parties to be reasonable for such purpose. The Receiving Party agrees that any breach of Section 8 of this Agreement may cause the Disclosing Party substantial and irreparable injury and, therefore, in the event of any
such breach, in addition to other remedies which may be available, the Disclosing Party may have the right to specific performance and other injunctive and equitable relief. 
 8.6 Caltech Name. Except as may be required by law, Cerulean shall not, without having first obtained written approval from Caltech, use the name
of Caltech, or California Institute of Technology, in any advertising or publicity material, or make any form of representation or statement which would constitute an express or implied endorsement by Caltech of any Licensed Product. 
 8.7 Laboratory Notebooks. The laboratory notebooks of Calando shall be made available to Cerulean upon the following terms and conditions:

 (a) All original laboratory notebooks and one complete unredacted electronic copy of the original laboratory notebooks shall be archived
[***] (the “Escrow Agent”) pursuant to the terms and conditions of the Three-Party Escrow Agreement (also known as the Technology Escrow Agreement) attached hereto as Exhibit K (the “Escrow
Agreement”). The master inventory list included as Exhibit D to the Escrow Agreement references each such laboratory notebook, including its assigned number and the inventor to whom the laboratory notebook was assigned, and whether such
laboratory notebook is a Full Access Notebook, Partial Access Notebook or Restricted Access Notebook. Such deposit with the Escrow Agent shall be made by Calando on or prior to the Effective Date and shall be released to Cerulean in accordance with
the terms of the Escrow Agreement.  
 (b) In addition, Cerulean shall be given, and granted full access to, one complete unredacted
electronic copy of the [***] laboratory notebooks of Calando that: (i) do not primarily relate to nucleic acids; (ii) contain disclosure related to the Assigned IP or Licensed IP; and (iii) do not contain proprietary
information of Third Parties (such notebooks, the “Full Access Notebooks”). 
  

 26 








 (c) Cerulean shall be given, and granted full access to, one redacted electronic copy of the [***]
laboratory notebooks of Calando that: (i) do not primarily relate to nucleic acids; (ii) contain disclosure related to the Assigned IP or Licensed IP; and (iii) contain proprietary information of Third Parties that is not
disclosure related to the Assigned IP or Licensed IP (such notebooks, the “Partial Access Notebooks”). Calando shall delete from such copy of such laboratory notebooks the proprietary information of Third Parties that is not
disclosure related to the Assigned IP or Licensed IP. 
 (d) Cerulean shall not be given or granted full access to any of the [***]
laboratory notebooks that are primarily related to nucleic acids and which may or may not contain proprietary information of Third Parties (such notebooks, the “Restricted Access Notebooks”). 
 (e) Notwithstanding the foregoing clauses (c) and (d), one complete unredacted electronic copy of the originals of each of the Full Access
Notebooks, Partial Access Notebooks and Restricted Access Notebooks shall be delivered to Cerulean on the Effective Date. Such copies of the Partial Access Notebooks and Restricted Access Notebooks shall be maintained in a secure location and access
to such copies shall be limited at all times to the most senior scientific officer of Cerulean, the most senior internal legal counsel of Cerulean and outside counsel of Cerulean. Cerulean, acting through such representatives, shall have the right
to refer to and use such copies of the Partial Access Notebooks and Restricted Access Notebooks solely: (i) for regulatory or governmental purposes pertaining to the Cyclodextrin System or any Licensed Product; (ii) in connection with any
litigation pertaining to the Cyclodextrin System or any Licensed Product; (iii) for the maintenance, prosecution or defense of the Assigned IP or Licensed IP; (iv) to resolve scientific or technical questions regarding the redacted
laboratory notebooks; and (v) to make corrections in the event that any disclosures related to the Assigned IP or Licensed IP were improperly or incorrectly redacted. 
 (f) Cerulean’s use of the Full Access Notebooks, whether the originals released by the Escrow Agent or the copies provided hereunder, shall be
unrestricted. 
 (g) In no event shall Cerulean have any right, nor is any right granted by Calando to Cerulean, to exploit any proprietary
information of Third Parties that is not Assigned IP or Licensed IP and is contained in any of the laboratory notebooks of Calando. 
 (h)
Title to and ownership of the Full Access Notebooks, Partial Access Notebooks and Restricted Access Notebooks shall remain with Calando. 
 SECTION 9. WARRANTIES 
 9.1 Mutual Warranties. Each Party warrants that: 
 (a) it is a corporation duly organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation, and it has full
power and authority and the legal right to own and operate its property and assets and to carry on its business as it is now being conducted and as it is contemplated to be conducted by this Agreement; 
 (b) it has the full right, power and authority to enter into this Agreement and to grant the rights and licenses granted by it under this Agreement;

 (c) as of the Effective Date, there is no existing or, to its Knowledge, threatened action, suit, claim, litigation, investigation,
proceeding or controversy pending before any court, administrative agency or other governmental authority with respect to (i) the subject matter of this Agreement, or (ii) its right to enter into and perform its obligations under this
Agreement; 
  

 27 








 (d) as of the Effective Date, it has taken all necessary corporate and stockholder action on its part to
authorize the execution and delivery of this Agreement and the performance of its obligations under this Agreement; 
 (e) this Agreement has
been duly executed and delivered on behalf of it, and constitutes a legal, valid, binding obligation, enforceable against it in accordance with the terms hereof, subject to the general principles of equity and to bankruptcy, insolvency, moratorium
and other similar laws affecting the enforcement of creditors’ rights generally; 
 (f) as of the Effective Date, all necessary
consents, approvals and authorizations of all governmental authorities and other persons required to be obtained by it in connection with the execution and delivery of this Agreement and the performance of its obligations under this Agreement have
been obtained; 
 (g) the execution and delivery of this Agreement and the performance of its obligations hereunder do not (i) conflict
with, or constitute a default under, any of its contractual obligations, (ii) conflict with or violate any provision of its Certificate of Incorporation, by-laws or other organizational documents; or (iii) violate any judgment, order,
writ, injunction, decree, statute, rule or regulation of any court, administrative agency or other governmental authority applicable to it or any of its properties or assets; and 
 (h) it has no liability or obligation to pay any fees or commissions to any broker, finder or agent with respect to the transactions contemplated by this
Agreement. 
 9.2 Additional Calando Warranties. Calando warrants to Cerulean that, as of the Effective Date: 
 (a) Good Title. Immediately prior to the Effective Date and the assignments pursuant to Section 2, (i) Calando was the sole, true and
lawful owner of, and had good title to, the Inventory, free and clear of all Liens of any kind; (ii) Calando is not, and has not been, bound by any policies or agreements under which the Inventory has been or will be assigned to anyone other
than Cerulean; (iii) Calando has the right to sell and transfer to Cerulean good, clear record and title to the Inventory, free and clear of all Liens of any kind; and (iv) upon execution and delivery to Cerulean of this Agreement and the
instruments of conveyance referred to in Section 2.2(e), Cerulean will become the sole, true and lawful owner of, and receive good and marketable title to, the Inventory, free and clear of all Liens. 
 (b) Inventory. All Inventory was manufactured in accordance with cGMP and the specifications set therefor by Calando and conform to such
specifications. Except for retain samples of IT-101 held at, and the drug substance and drug product that are subject to the stability studies being conducted by, [***], no drug substance or drug product form of IT-101 is stored or exists
anywhere other than at [***]. 
 (c) Government Rights. Calando, its Affiliates and Caltech have neither sought, applied for
nor received any support, funding, resources or assistance from any governmental authority in connection with the development, conception or reduction to practice of the Licensed IP or the research, development, manufacturing, having made, use,
marketing, offering to sell, distribution, sale or importation of the Licensed Product or any facilities or equipment used in connection therewith. 
  

 28 








 (d) Completeness. Exhibits A, B, C and D collectively list all Patent Rights owned, solely
or jointly, by Calando or its Affiliates and/or Controlled by Calando that relate to the Cyclodextrin System or the Licensed Product, in each case immediately prior to the assignment of the Assigned Patent Rights pursuant to Section 2.2 of the
Platform Agreement. Such exhibits accurately list, for each such Patent Right: the applicable serial number, filing date, title, jurisdiction in which filing was made, issue date and owners(s). 
 (e) Patent Validity. To Calando’s Knowledge, (i) all issued patents included in the Collective Patent Rights are valid and enforceable;
(ii) no claim has been made against Calando, its Affiliates or the Third Party co-owner thereof alleging that any issued patent included in the Collective Patent Rights is invalid or unenforceable; (iii) all assignments of such Patent
Rights have been properly executed and recorded; (iv) all issuance, renewal, maintenance and other payments that are or have become due with respect thereto have been timely paid by or on behalf of Calando or the Third Party co-owner thereof;
(v) there are no inventorship challenges, opposition or nullity proceedings or interferences declared, commenced or provoked with respect to any Collective Patent Rights; and (vi) with respect to any Licensed Patent Rights owned, in whole
or in part, by Calando, Calando and its Affiliates have, and any co-owner of such Patent Rights has, complied with the duty of candor and disclosure to the United States Patent and Trademark Office and any relevant foreign patent office and have
made no material misrepresentation in any patent applications included in or underlying such Patent Rights. Calando has no Knowledge of any information that would preclude it from owning the Assigned IP (immediately prior to the assignment pursuant
to Section 2.2 of the Platform Agreement) or the Licensed Patent Rights described in clause (vi) hereof. 
 (f) Non-Infringement
of Third Party Rights. There are no claims pending or, to the actual knowledge of the Calando Representatives, threatened by any person against Calando or any of its Affiliates alleging that Calando’s ownership, sale, licensing, possession
or use of, or disclosure, transfer, license or assignment (as applicable) to Cerulean of, the Inventory, or Licensed IP infringes upon or constitutes an unauthorized use of the intellectual property rights of any person, nor is there any known basis
for any such claim. Except as previously disclosed to the General Counsel of Cerulean, to the actual knowledge of the Calando Representatives, the research, development, making, having made, use, offering for sale, distribution, sale or importation
of IT-101 by or on behalf of Cerulean, its Affiliates or sublicensees after the Effective Date, will not infringe or misappropriate any intellectual property right of any Third Party. Calando and its Affiliates have not received any complaint, claim
or notice, nor any threat thereof (including any notification that a license under any Patent Right or other intellectual property right is or may be required), alleging any such infringement or misappropriation. 
 (g) Non-Infringement by Third Party. To Calando’s Knowledge, no person (including any current or former employee or consultant of Calando) is
infringing, violating or misappropriating any of the Licensed IP in the Field. 
 (h) Corporate Documents. Calando has furnished to
Cerulean true, complete and accurate copies of (i) its current Certificate of Incorporation and by-laws; (ii) all material documentation pertaining to the formation of the previous corporate entity known as Calando Pharmaceuticals, Inc.,
the subsequent merger of such corporate entity into Insert Therapeutics, Inc. and the subsequent change in the name of Insert Therapeutics, Inc. to Calando Pharmaceuticals, Inc.; (iii) its stock ledger going back to the inception of Calando or
its 
  

 29 








 predecessor and a list of all current stockholders of Calando; (iv) all documentation for any repurchased or
cancelled shares of stock of Calando; (v) all option plans, option agreements, warrants and other rights to purchase equity of Calando (including any exercises) and the ledger(s) listing current holders thereof; (vi) all promissory notes
of Calando and a ledger listing all current holders thereof; (vii) all agreements relating to the sale of equity of Calando; (viii) all board of director and stockholder minute books dating to the inception of Calando or its predecessor;
and (ix) any other Relevant Agreement (A) under which a Lien has been or could be imposed on any of the Assigned IP, Licensed IP or Inventory and (B) any agreement that restricts or could reasonably be expected to have the effect of
restricting the rights granted to Cerulean hereunder. 
 (i) Approvals. This Agreement and the transactions contemplated hereby have
been approved by Calando’s board of directors and stockholders in accordance with the corporate laws of the state of Delaware, including Section 144 of the Delaware General Corporation Law. 
 (j) Solvency. Neither Calando nor any of its Affiliates has ever filed in any court or agency pursuant to any statute or regulation of any state
or country, a petition in bankruptcy or insolvency or for reorganization or for an arrangement or for the appointment of a receiver or trustee of it or its assets. Neither Calando nor any of its Affiliates has been served with an involuntary
petition against it, filed in any insolvency proceeding. Neither the execution and delivery of this Agreement nor the consummation of the transactions contemplated hereby will result in the imposition of any Lien upon any assets of Calando.

 (k) Clinical Trials. Exhibit L lists each person with which Calando or any of its Affiliates has executed any agreement, or
to which any units of Licensed Product have been shipped on or before the Effective Date, for purposes of conducting any Clinical Trial (each, a “Clinical Trial Site”). To Calando’s Knowledge, each patient involved in a
Clinical Trial of the Licensed Product has executed an informed consent (in substantially the form provided to Cerulean by Calando) and a HIPAA authorization. To Calando’s Knowledge, all Clinical Trials conducted on the Licensed Product have
been conducted in compliance in all material respects with the relevant protocol and any and all applicable laws, regulations and guidelines, and any other relevant professional standard relating to the conduct of the Clinical Trial and the
performance of clinical investigations, including such laws, rules and regulations concerning or promulgated by the FDA. The IT-101 IND is the only IND covering the Licensed Product. Calando has provided Cerulean with a true and complete copy of all
Regulatory Documentation generated on or before the Effective Date with respect to IT-101. 
 (l) Debarment. Neither Calando, any
Affiliate of Calando, or to Calando’s Knowledge, any Clinical Trial Site, investigator or any other person who provided or is providing services in any capacity involved in any Clinical Trial of the Licensed Product (each, a “Clinical
Trial Investigator”): (i) is or was subject to any pending or threatened, investigation by (A) the FDA pursuant to its “Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities” policy set forth in 56
Fed. Reg. 46191 (September 10, 1991) or any amendments thereto, (B) the Department of Health and Human Services Office of Inspector General or Department of Justice pursuant to the Federal Anti-Kickback Statute (42 U.S.C. §1320a-7(b)) or
the Civil False Claims Act (31 U.S.C. §§3729 et seq.), or (C) any equivalent statute of any other country; (ii) committed any act, made any statement or failed to make any statement that would reasonably be expected to provide a
basis for action under any of the statutes, regulations, and policy referred to in clause (i); or (iii) has been convicted of any crime or engaged in any conduct that would reasonably be expected to result in (A) debarment under 21 U.S.C.
§335a or any similar state or foreign law or 
  

 30 








 (B) exclusion under 42 U.S.C. §1320a-7 or any similar state or foreign law. No data generated by any Clinical Trial
Investigator in connection with any Clinical Trial of any Licensed Product is the subject of any pending regulatory action by the FDA or any other Regulatory Authority relating to the truthfulness or scientific adequacy of such data. 
 9.3 Disclaimer. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS SECTION 9, NEITHER PARTY MAKES ANY REPRESENTATIONS OR EXTENDS ANY WARRANTIES OF
ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY, QUALITY, FITNESS FOR A PARTICULAR PURPOSE, NONINFRINGEMENT, OR VALIDITY OF PATENT CLAIMS. 
 SECTION 10. INDEMNIFICATION 
 10.1 Indemnification by Cerulean. Cerulean agrees to defend the
Calando Indemnitees, at Cerulean’s cost and expense, and will indemnify and hold harmless the Calando Indemnitees from and against any and all losses, costs, damages, fees or expenses (“Losses”) relating to or in connection
with a Third Party claim arising out of (a) any actual or alleged death, personal bodily injury or damage to real or tangible personal property claimed to result, directly or indirectly, from the possession, use or consumption of, or treatment
with, any Licensed Product, developed, manufactured, used or sold by or on behalf of Cerulean, its Affiliates or sublicensees after the Effective Date; (b) any breach by Cerulean of its representations, warranties or covenants made under this
Agreement; or (c) any negligent act or omission or willful misconduct of Cerulean, its Affiliates or sublicensees or any of their employees, contractors or agents, in performing Cerulean’s obligations or exercising Cerulean’s rights
under this Agreement; provided, however, that the foregoing indemnity shall not apply to the extent that any such Losses (i) are attributable to the gross negligence or willful misconduct of the Calando Indemnitees, or
(ii) are otherwise subject to an obligation by Calando to indemnify the Cerulean Indemnitees under Section 10.2. In the event of any such claim against any Calando Indemnitee, Calando shall promptly notify Cerulean in writing of the claim
and Cerulean shall manage and control, at its sole expense, the defense of the claim and its settlement as provided below. The relevant Calando Indemnitees shall cooperate with Cerulean and may, at such Calando Indemnitees’ option and expense,
be represented in any such action or proceeding. Cerulean shall not be liable for any settlements, litigation costs or expenses incurred by any Calando Indemnitees without Cerulean’s written authorization. No Calando Indemnitee shall settle any
such claim without the prior written consent of Cerulean. Cerulean shall not, without the prior written consent of Calando, agree to any settlement of any such claim that does not include a complete release of Calando from all liability with respect
thereto or that imposes any liability, obligation or restriction on Calando. 
 10.2 Indemnification by Calando. Calando agrees to
defend the Cerulean Indemnitees, at Calando’s cost and expense, and will, jointly and severally with Arrowhead, indemnify and hold harmless the Cerulean Indemnitees from and against any and all Losses relating to or in connection with a Third
Party claim arising out of (a) any research, development, manufacture, use, sale, offer for sale or importation of the Licensed Product by or on behalf of Calando, its Affiliates or licensees which activity occurred on or before the Effective
Date, including claims arising out of the Clinical Trials of IT-101 conducted by or on behalf of Calando, its Affiliates or licensees prior to the Effective Date; (b) any breach by Calando of its representations, warranties or covenants made
under this Agreement or any breach by Arrowhead of its representations, warranties or covenants made under the Arrowhead Guarantee; or (c) any negligent act or omission or willful misconduct of Calando or its Affiliates, or any of their
employees, contractors or agents, in performing Calando’s obligations or exercising Calando’s 
  

 31 








 rights under this Agreement; provided, however, that the foregoing indemnity shall not apply to the extent
that any such Losses (i) are attributable to the gross negligence or willful misconduct of the Cerulean Indemnitees, or (ii) are otherwise subject to an obligation by Cerulean to indemnify the Calando Indemnitees under Section 10.1.
In the event of any such claim against any Cerulean Indemnitee, Cerulean shall promptly notify Calando in writing of the claim and Calando shall manage and control, at its sole expense, the defense of the claim and its settlement as provided below.
The relevant Cerulean Indemnitees shall cooperate with Calando and may, at such Cerulean Indemnitees’ option and expense, be represented in any such action or proceeding. Calando shall not be liable for any settlements, litigation costs or
expenses incurred by any Cerulean Indemnitees without Calando’s written authorization. No Cerulean Indemnitee shall settle any such claim without the prior written consent of Calando. Calando shall not, without the prior written consent of
Cerulean, agree to any settlement of any such claim that does not include a complete release of Cerulean from all liability with respect thereto or that imposes any liability, obligation or restriction on Cerulean. 
 10.3 Allocation. If a claim is based partially on an indemnified claim and partially on a non-indemnified claim or based partially on a claim
indemnified by one Party and partially on a claim indemnified by the other Party, any payments in connection with such claims are to be apportioned between the Parties in accordance with the degree of cause attributable to each Party. 
 SECTION 11. LIMITATION OF LIABILITY 
 11.1 UNLESS RESULTING FROM A PARTY’S WILLFUL MISCONDUCT OR FROM A PARTY’S BREACH OF SECTION 8, NEITHER PARTY WILL BE LIABLE TO THE OTHER PARTY OR ITS AFFILIATES FOR SPECIAL, INCIDENTAL, CONSEQUENTIAL, EXEMPLARY, PUNITIVE, MULTIPLE
OR OTHER INDIRECT DAMAGES, OR FOR LOSS OF PROFITS, LOSS OF DATA, LOSS OF REVENUE, OR LOSS OF USE DAMAGES, ARISING FROM OR RELATING TO THIS AGREEMENT, WHETHER BASED UPON WARRANTY, CONTRACT, TORT, NEGLIGENCE, STRICT LIABILITY OR OTHERWISE, REGARDLESS
OF ANY NOTICE OF SUCH DAMAGES. FOR PURPOSES OF CLARITY, A PARTY’S INDEMNIFICATION OBLIGATIONS UNDER SECTION 10 OF THIS AGREEMENT SHALL NOT BE DEEMED TO BE INDIRECT DAMAGES PRECLUDED BY THE FOREGOING. 
 SECTION 12. TERM AND REMEDIES 
 12.1
Term. This Agreement shall commence on the Effective Date and shall continue until the expiration of all royalty obligations under Section 5.5 (the “Term”); provided, however, that Cerulean shall have the
right to terminate this Agreement at any time and for any reason upon thirty (30) days prior written notice to Calando. Unless Cerulean has certified in good faith to Calando in such termination notice that such termination was not made, in
whole or in part, for a Safety Concern, then upon such termination by Cerulean, Cerulean shall (a) grant to Calando an exclusive (even as to Cerulean), transferable (as permitted pursuant to Section 13.1), irrevocable and perpetual,
royalty-free, worldwide license, with the right to grant sublicenses, under the Assigned Patent Rights solely in order to research, develop, make, have made, use, market, offer to sell, distribute, sell and import Licensed Products in the Field, and
(b) assign to Calando all right, title and interest in the IT-101 IND. Further, if Cerulean determines, in its sole discretion, that such a [***], Cerulean agrees to [***] to such [***], and the [***], which [***]
after the Effective Date and which [***]. “Safety Concern” means any toxicity, serious adverse event, side effect, issue associated with the therapeutic index, or other safety finding, whether in vitro, in animals or in
humans, that leads to a determination that IT-101 exposes or could expose animals or humans to an unacceptable safety risk in relation to therapeutic benefit. 
  

 32 








 12.2 Remedy for Breach. If a Party (the “Breaching Party”) is in breach of a
material provision of this Agreement (including any breach of a material representation or warranty made in this Agreement), then the other Party (the “Non-Breaching Party”) may deliver notice of such breach to the Breaching Party.

 (a) If the Breaching Party fails to cure such breach within ninety (90) days after the Breaching Party’s receipt of such notice,
then the Non-Breaching Party may seek money damages from the Breaching Party with respect to such breach, which shall be the Non-Breaching Party’s sole remedy, except as provided in Sections 5.7, 12.2(b) or 12.2(c). 
 (b) If Cerulean has breached a payment obligation under Section 5 and Cerulean fails to cure such payment breach within thirty (30) days after
Cerulean’s receipt of such notice, then Calando may, upon written notice to Cerulean, terminate this Agreement; provided, however, that if Cerulean disputes such breach, Calando may not terminate this Agreement unless and until
such dispute is finally resolved in Calando’s favor and Cerulean fails to cure such payment breach within thirty (30) days after such final resolution. In the case of a termination, Cerulean shall (i) grant to Calando an exclusive
(even as to Cerulean), transferable (as permitted pursuant to Section 13.1), irrevocable and perpetual, royalty-free, worldwide license, with the right to grant sublicenses, under the Assigned Patent Rights solely in order to research, develop,
make, have made, use, market, offer to sell, distribute, sell and import Licensed Products in the Field, and (ii) assign to Calando all right, title and interest in the IT-101 IND. 
 (c) If Cerulean has breached its obligations under Section 6.1 and Cerulean fails to cure such breach within ninety (90) days after
Cerulean’s receipt of such notice, then Calando may, upon written notice to Cerulean, convert the license granted in Section 3.1 to a non-exclusive license; provided, however, that if Cerulean disputes such breach, Calando
may not convert such license unless and until such dispute is finally resolved in Calando’s favor and Cerulean fails to cure such breach within ninety (90) days after such final resolution. In the case of a conversion to non-exclusivity,
the royalties payable under this Agreement, as determined in accordance with Section 5.5, shall be reduced by [***] and Cerulean shall grant to Calando a non-exclusive, transferable (as permitted pursuant to Section 13.1),
irrevocable and perpetual, royalty-free, worldwide license, with the right to grant sublicenses, under the Assigned Patent Rights solely in order to research, develop, make, have made, use, market, offer to sell, distribute, sell and import Licensed
Products in the Field. 
 12.3 Challenges to Licensed Patent Rights. If Cerulean or an Affiliate of Cerulean challenges the validity
or enforceability of any of the Licensed Patent Rights before any court, arbitrator or other tribunal or administrative agency in any jurisdiction, Calando shall have the right to terminate this Agreement on thirty (30) days prior written
notice to Cerulean 
 12.4 Consequences of Termination. 
 (a) Upon any termination of this Agreement, the license to Cerulean of the Licensed IP shall terminate subject to the following. Cerulean shall, within thirty (30) days of the effective date of such termination,
notify Calando in writing of the amount of Licensed Products which Cerulean and its Affiliates and Sublicensees then have completed in inventory, the sale of which would, but for the termination, be subject to royalty payments or payment of a
portion of 
  

 33 








 Sublicense Income, and Cerulean and its Affiliates and Sublicensees shall thereupon be permitted during the six
(6) months following such termination to sell that amount of Licensed Products; provided, however, that Cerulean shall pay the aggregate royalty or portion of Sublicense Income due thereon at the conclusion of the earlier of sixty
(60) days after the last such sale or sixty (60) days after the end of such six (6)-month period. Except as provided herein, all sublicenses granted by Cerulean shall terminate upon the termination of this Agreement. 
 (b) Upon any termination of this Agreement, neither Party shall be relieved of any obligations incurred prior to such termination. 
 (c) Upon any termination of this Agreement, each Party shall promptly return to the other Party all tangible Confidential Information of the other Party.

 (d) The following provisions shall survive the expiration or termination of this Agreement: Sections 2, 3.3 (if applicable), 5.9, 7.1,
7.2(a), 7.3(b), 8, 9.3, 10, 11, 12.1 (with respect to the license granted and the assignment made thereunder, if applicable), 12.2(b) (with respect to the license granted and the assignment made thereunder, if applicable), 12.4 and 13. Any licenses
granted under Section 5.5(b)(iii) on or before the effective date of expiration or termination of this Agreement shall survive the expiration or termination of this Agreement. 
 SECTION 13. MISCELLANEOUS 
 13.1 Assignment. Neither this Agreement nor
any of the rights or obligations hereunder may be assigned by either Party without the prior written consent of the other Party, except (a) each Party may assign this Agreement, in whole or in part, to an Affiliate of the assigning Party;
provided, that the assigning Party guarantees the performance of such Affiliate of its obligations hereunder; (b) each Party may assign this Agreement, in whole, to a person who acquires all or substantially all of the business of the
assigning Party by merger, sale of assets or otherwise (a “Sale Event”); and (c) each Party may exercise its rights or fulfill its obligations through its Affiliates, consultants, subcontractors and sublicensees;
provided, that, such persons are bound by the corresponding obligations of such Party and such Party shall remain liable hereunder for the performance of its obligations hereunder. Any assignment not in accordance with the foregoing shall be
void. Notwithstanding anything to the contrary herein, Calando shall not (i) assign this Agreement, in whole or in part, to any person unless Calando simultaneously assigns to such person all right, title and interest in, to and under the
Licensed IP, the Caltech Agreement and the Caltech Side Letter, and (ii) assign any right, title or interest in or to the Licensed IP, except subject to the rights of Cerulean under this Agreement. This Agreement shall be binding upon, and
shall inure to the benefit of, all permitted successors and assigns. 
 13.2 Governing Law. This Agreement shall be governed by and
interpreted in accordance with the laws of the State of Delaware, excluding its conflicts of laws provisions. 
 13.3 Dispute
Resolution. Any dispute, controversy or claim arising out of or relating to this Agreement, or the breach, termination or invalidity thereof, shall be resolved as follows: 
 (a) The chief executive officers of the Parties shall attempt to resolve such dispute through good faith negotiation. Any such resolution of a referred
dispute by the chief executive officers shall be final and binding on the Parties. 
  

 34 








 (b) If the Parties’ chief executive officers cannot resolve such dispute within thirty
(30) days after either Party provides written notice of such dispute, then either Party may make a written demand for formal dispute resolution. 
 (c) Within thirty (30) days after such written demand, the Parties shall conduct a non-binding mediation administered by the American Arbitration Association in accordance with its commercial mediation rules.
Unless otherwise mutually agreed upon by the Parties, the mediation proceedings shall be conducted at the location chosen by the Party not originally requesting the resolution of the dispute. The Parties shall share equally the cost of the
mediation, including filing and hearing fees and the cost of the mediator(s). Each Party shall have the right, at its own expense, to be represented by counsel in such a proceeding. 
 (d) If such dispute is not resolved following mediation pursuant to Section 13.3(c), either Party may seek any remedy, at law or in equity, that may
be available to it. 
 (e) Notwithstanding the foregoing provisions of this Section 13.3, each Party shall have the right at any time to
institute judicial proceedings against the other Party or anyone acting by, through or under such other Party, in order to enforce the instituting Party’s rights hereunder through reformation of contract, specific performance, injunction or
similar equitable relief. 
 13.4 Amendment and Waiver. This Agreement may not be amended, nor any rights hereunder waived, except in
a writing signed by the properly authorized representatives of each Party. The waiver by either Party of a breach or a default of any provision of this Agreement by the other Party shall not be construed as a waiver of any succeeding breach of the
same or any other provision, nor shall any delay or omission on the part of either Party to exercise or avail itself of any right, power or privilege that it has or may have hereunder operate as a waiver of any right, power or privilege by such
Party. 
 13.5 Notices. Any notice required or provided for by the terms of this Agreement shall be in writing, in the English
language, and shall be (a) sent by certified mail, return receipt requested, postage prepaid, (b) sent via a reputable overnight air courier service, or (c) delivered by hand. Notices shall be effective when delivered to the addressee
at the address listed in the first paragraph of this Agreement or such other address as the addressee shall have specified in the manner provided in this Section 13.5. The effective date of the notice shall be the actual date of receipt by the
receiving Party. 
 13.6 No Agency. Nothing herein shall be deemed to constitute either Party as the agent or representative of the
other Party or both Parties as joint venturers or partners for any purpose. Neither Party shall be responsible for the acts or omissions of the other Party, and neither Party will have authority to speak for, represent or obligate the other Party in
any way without prior written authority from the other Party. Except for the Calando Indemnitees and the Cerulean Indemnitees, no person shall be a third party beneficiary of this Agreement. 
 13.7 Entire Agreement. This Agreement contains the full understanding of the Parties with respect to the subject matter hereof and supersedes all
prior understandings and writings relating thereto, including the Prior Confidentiality Agreement; provided, however, that the Parties agree and acknowledge that the Platform Agreement, the Escrow Agreement and the Caltech Side Letter
are being entered into concurrently herewith or have been entered into prior to the Effective Date and shall remain in effect. 
  

 35 








 13.8 Force Majeure. Neither Party will be held liable or responsible to the other Party nor be
deemed to have breached this Agreement for failure or delay in fulfilling or performing any provision of this Agreement when such failure or delay results from causes beyond the reasonable control of the affected Party, which may include embargoes,
acts of war (whether declared or not), insurrections, riots, civil commotions, acts of terrorism, strikes, lockouts or other labor disturbances, or acts of God. The affected Party will notify the other Party of such force majeure circumstances as
soon as reasonably practical and will make every reasonable effort to mitigate the effects of such force majeure circumstances. 
 13.9
Severabilitv. If any provision of this Agreement is held by a court of competent jurisdiction to be unenforceable because it is invalid or in conflict with any law of any relevant jurisdiction, the validity of the remaining provisions shall
not be affected, and the rights and obligations of the Parties shall be construed and enforced as if the Agreement did not contain the particular provisions held to be unenforceable. 
 13.10 Export Compliance. The Parties acknowledge that the exportation from the United States of materials, products and related technical data
(and the re-export from elsewhere of United States origin items) may be subject to compliance with United States export laws. Each Party shall comply with all applicable laws (whether U.S. or foreign) relating to the export, re-export, or release of
any materials, products or their related technical data. 
 13.11 Counterparts and Facsimile Signatures. This Agreement may be
executed in any number of counterparts, each of which shall be deemed an original, and all of which together shall constitute one and the same instrument. This Agreement may be executed by facsimile signature. 
 13.12 Construction. In construing this Agreement, unless expressly specified otherwise; 
 (a) references to Sections and Exhibits are to sections of, and exhibits to, this Agreement; 
 (b) use of either gender includes the other gender, and use of the singular includes the plural and vice versa; 
 (c) headings and titles are for convenience only and do not affect the interpretation of this Agreement; 
 (d) any list or examples following the word “include” or “including” shall be interpreted without limitation to the generality of the
preceding words; and 
 (e) the language used in this Agreement shall be deemed to be the language chosen by the Parties to express their
mutual intent, and no rule of strict construction shall be applied against either Party. 
 [Remainder of Page Intentionally Left Blank]

  

 36 








 IN WITNESS WHEREOF, the Parties hereto have caused this IT-101 Agreement to be executed as a sealed
instrument in their names by their properly and duly authorized officers or representatives as of the date first above written. 
  

			
	CERULEAN PHARMA INC.
		
	By:	 	 /s/    Oliver Fetzer

	Name:	 	Oliver Fetzer
	Title:	 	Chief Executive Officer


  

			
	CALANDO PHARMACEUTICALS, INC.
		
	By:	 	 /s/    Christopher Anzalone

	Name:	 	Christopher Anzalone
	Title:	 	Chief Executive Officer


 Arrowhead Research Corporation, hereby (a) guarantees Calando’s performance under this Agreement,
(b) makes the same representations and warranties to Cerulean as Calando makes to Cerulean under Section 9.1 and clauses (h)-(j) of Section 9.2, and (c) agrees to indemnify Cerulean to the same extent as Calando indemnifies
Cerulean pursuant to Section 10.2 from any Losses relating to or in connection with a Third Party claim arising out of any breach by Arrowhead of its representations or warranties as described in clause (b), and for which indemnification
Calando and Arrowhead shall be jointly and severally liable to Cerulean and the Cerulean Indemnitees. 
  

			
	ARROWHEAD RESEARCH CORPORATION
		
	By:	 	 /s/    Christopher Anzalone

	Name:	 	Christopher Anzalone
	Title:	 	Chief Executive Officer


  

 37